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There is a need for a common way of documenting and planning pharmaceutical 
care within the electronic prescribing system used at Ayr hospital. 
 
Aims and objectives 
Conduct a contents analysis of care issues in a formal survey of the care plans in 




Documentation of pharmaceutical care and the distribution of care issues in two 
different settings were investigated in a prospective, clinical audit. A categorisation 
system was modified and guideline for this categorisation system was made, and 
documented care issues were subsequently subject to content analysis in the 
system. All results were evaluated in a focus group. A proposal for an electronic care 
plan template was made 
 
Results 
It was confirmed in a focus group meeting that the electronic care plan template had 
captured the needs set by the pharmacists at Ayr Hospital. The validity and usability 
of the different parts of the categorisation system differed. The content analysis of 
care issues between two wards at Ayr Hospital showed differences in the mean value 




An electronic care plan template have great potentials. The categorisation system as 







ACE inhibitor  Angiotensin Converting Enzyme inhibitor 
ACS   Acute Coronary Syndrome 
A/E   Accidents and emergencies unit 
AF   Atrial Fibrillation 
aPTT   Activated Partial Thromboplastin Time 
BMI   Body Mass Index 
BP   Blood Pressure 
CI   Confidence interval 
COPD   Chronic Obstructive Pulmonary Disease 
CP   Chest Pain 
DRP   Drug-Related Problem 
DTP   Drug Therapy Problem  
ECS    Electronic Care Summary 
EPA   Electronic Prescribing and Administration 
EPMA   Electronic Prescribing and Medicine Administration 
EPS   Electronic Prescribing System 
IDDM   Insulin Dependant Diabetes Mellitus 
IQR   Inter Quartile Range 
INR   International Normalised Ratio 
LRTI   Lower respiratory tract infection 
MM   Medicines Management 
NKDA   No Known Drug Allergies 
NSTEMI  Non-ST Elevated Myocardial Infarction 
OTC   Over the counter medicines, non-prescription medicines 
PCP   Pharmaceutical care plan 
PIP   Pharmacist Independent Prescriber 
PODs   Patient’s own drugs 
POE   Prescription Order Entry, an EPS/EPA system 
PRN   Pro Re Nata = as required 
PSP   Pharmacist Supplementary Prescriber 
RF   Renal function 
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R/v   Review 
SD   Standard Deviation 
STEMI  ST Elevated Myocardial Infarction 
TAH    The Ayr Hospital 
TFTs   Thyroid Function Tests 
TTA   To Take Away, Medicines prescribed for discharge 
TID   Three times a day 
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1.1 Pharmaceutical care 
 
Pharmaceutical care is defined by Hepler and Strand as “the responsible provision of 
drug therapy for the purpose of achieving definite outcomes that improve a patient’s 
quality of life”1. 
 
Pharmaceutical care is what the patient receives in terms of better drug therapy, and 
this is a result of what the whole medical team provides to the patient. The pharmacist 
is the health care worker who leads the pharmaceutical care provision, but i.e. 
doctors and nurses are involved in the delivery of this care. 
 
 
1.1.1 Pharmaceutical care provided by the clinical pharmacist 
 
Clinical pharmacy emerged in the US in mid 1960s2 , and both hospital pharmacy and 
community pharmacy have changed a lot since then, along with the educational 
establishments. To day there are clinical study programmes in i.e. USA, Canada, 
Japan, Australia, Netherlands, Spain and the UK 2, 3. In Europe the UK is well 
advanced with several universities offering masters degrees in clinical pharmacy and 
courses in pharmacist prescribing. 
 
The pharmacist is a drug expert with broad knowledge on several aspects regarding 
medicines; like pharmacology, drug manufacturing, pharmacy practice, 
pharmaceutics, biochemistry, pharmacokinetics and medical microbiology. The 
pharmacists thus have unique competences and skills, and can contribute with new 
aspects regarding patient specific drug therapy, in addition to supporting already 
existing services. In the pharmaceutical care team the pharmacist is the only health 
professional that is an expert on medicaments. The education and experiences of 
pharmacists give them another perspective regarding drug use compared with 
doctors or nurses. Pharmaceutical care is a care practice on the same level as for 
instance nursing care and mental health care, and is therefore something more than 
a support service. 
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The pharmacy profession has altered with the emergence of clinical pharmacy, and 
“clinical pharmacy is a move away from the re-active quality control towards pro-
active involvement in direct patient care and the anticipation of errors”4. The clinical 
pharmacist have a greater opportunity to anticipate potential drug therapy problems 
compared with the dispensing pharmacists, due to access to the patient’s medical 
notes and the closer co-operation with the patient’s care team. The pharmacist’s 
expertise is therefore well utilised in a clinical setting. The clinical pharmacist’s 
provision of pharmaceutical care can be described as a cyclic process where the 
patient’s needs and treatment is reviewed continuously. 
 
 
1.2 The pharmaceutical care plan 
 
The pharmaceutical care plan is a tool the pharmacist uses when providing 
pharmaceutical care. The plan has two main functions; to facilitate that the patient is 
provided pharmaceutical care as needed, and to document what actions the 
pharmacist has undertaken to ensure the delivery of pharmaceutical care. A good 
care plan helps to deliver pharmaceutical care in a structured manner by giving the 
pharmacist an overview of which care issues that needs to be reviewed and which 
ones that already are sorted. A care plan should ideally include 3 main parts5: 
1. A statement of the goals of the therapy/therapies 
2. The actions the practitioner has identified as necessary to be undertaken to 
resolve any drug therapy problems, to meet the goals of therapy, and prevent 
drug therapy problems 
3. A schedule for follow-up evaluation or a review of the care plan 
 
More precisely the pharmaceutical care plan should contain the following information: 
1) Patient characteristics  
a) Patient demographics 
b) Presenting complaints 
c) Past medical history 
d) Allergy status 
e) Relevant drug history 
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2) Current drug regimen 
3) Relevant investigations 
4) Care issues presented in an orderly manner which clearly states and documents: 
a) Desired outcome 
b) Actions needed to be undertaken or that already are undertaken 
c) Outcomes 
d) Review dates 
5) The care issues should include plans for pharmaceutical care in the present 
setting and also for continuity of care between settings where this is relevant. 
a) Verification of present drug regime 
b) Monitoring of drug use and effects and side effects, need for further 
medication, general lab values 
c) A plan for discharge 
 
A care plan made by a pharmacist that sees the patient over a longer time period, for 
instance in a primary care setting, will differ from a care plan made by a pharmacist 
that sees the patient in a interim setting, for instance at a hospital ward. The following 
section describes what an ideal care plan for use in a hospital setting should contain. 
 
 
1.2.1 Use of patient demographics  
 
The risk of acquiring different diseases changes with age, gender, lifestyle, body 
weight, social drug use, smoking, occupation and living situation. Recommended 
drug therapies also varies with these demographic parameters, and these patient 
specific information should therefore be noted in the pharmaceutical care plan, 
among others as this information is relevant when evaluating  the patients drug 
therapy. Usually recommended dosing regimes are made based on the average 
patient who is male, 55 years old, weighs 70 kg and has a body surface area of 1.73 
m2. 
 
Age:  Absorption, metabolism and elimination changes with age. Factors that are 
important to bear in mind when assessing doses for elderly patients, are that renal 
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function decline with 1 percent  after 20 years of age, and that it is estimated that liver 
function declines at a similar rate. 
 
Gender: The body composition  differs between men and women, with women having 
a higher percentage of adipose tissue than men, women also have a lower average 
height and thereby also a lower a body weight. 
 
Height and weight: For lipophilic substances such as for instance benzodiazepines 
and theophylline, weight is generally a good measure for dosing, but for hydrophilic 
drugs which often are excreted unchanged by the kidneys, such as atenolol, doses 
should be estimated based on ideal weight and creatinine clearance. High dose 
cytostatics and certain drugs when they are used to treat children, needs to be dosed 
according to body surface area. Even though there are exceptions, a high BMI may 
indicate overweight or obesity, and should therefore be noted by the pharmacist. The 
pharmacist can give the patient advices regarding diet and exercise, or identify a 
need for the patient to be referred to a dietician. 
 
Occupation: Some drugs should be used with caution in relation to some 
occupations; for instance shouldn’t drugs that cause drowsiness be used when 
driving or operating heavy machinery, and a person that travels a lot should be aware 
of the regulations that applies to bringing prescribed medicines classified as narcotics 
out of the UK.  
 
Living situation and compliance: It is relevant to know if a patient that needs help 
with administering their medicines within primary care, already has someone helping 
them with this, or if it should be arranged for continuity of care. Notes should also be 
made about the use of compliance aids such as blister packs and etc. 
 
 
1.2.2 Presenting complaints and past medical history 
 
This section should contain a short presentation of the reason for the hospitalisation. 
Sometimes a diagnosis is yet to be set when the pharmacist first sees the patient, 
and symptoms should then be presented in stead.  
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The patient’s relevant medical history gives a broader understanding of the patient’s 
clinical condition, and it is therefore important that the clinical pharmacist acquire this 
information. If the ward pharmacist only has limited time to spend on a patient, the 
focus for the pharmaceutical care provision will often be the presenting complaints, 
but nevertheless past medical history should always be reviewed as co-morbidities 
inevitably may affect the condition currently presented. These co-morbidities and the 
medications used to treat them may reveal pharmaceutical care issues of high 




1.2.3 Drug history 
 
The complete current drug regimen is an essential section of the pharmaceutical care 
plan, and should either be incorporated in it or attached as an appendix. An important 
part of the pharmacists provision of pharmaceutical care is to clarify a correct drug 
history. A detailed and accurate drug history helps to prevent both that the patient is 
receiving inappropriate drugs, as well as it reduces the number of omitted drugs, both 
which may deteriorate the patient’s condition. By taking an accurate drug history the 
pharmacist therefore helps to lower the number of errors in prescribing. 
 
A prospective audit that compared junior doctor and pharmacists accuracy in taking 
drug history, found that junior doctors transcribed errors to 65% of their patients drug 
chart, while pharmacists transcribed errors to 5% of their patients charts.6 The higher 
error rate for doctors was partly explained by an over reliance on the GP letters. A 
weakness with the survey design were that the pharmacists knew about the survey, 






Table 1 Checks conducted when drugs on admittance and newly prescribed drugs are 
verified 
• Discrepancies between patients drug regimen on admittance and transcribed 
drug regime 
• Indication for drug therapy 
• Right medicine 
• Right dose of medicine 
• Right dosing interval for the medicine 
• Right dosing time 
• Need for additional medicine due to transcription discrepancies/missed 
regularly used OTCs 
• Unnecessary medicines 






Table 2 Sources to confirm a patient’s current drug regimen 
• Patient 
• Patient’s relatives 
• GP referral letter 
• GP surgery 
• Community pharmacy 
• Previous discharge letter 
• PODs brought in 
• Medical notes 
• Nursing home 
• ECS (Electronic Care Summary) System 
 
 
Speaking with the patient or the patient’s relatives/closest care takers is of great 
value, since this will clarify which drugs the patient really used on admission. The 
patient’s actual drug regimen may differ from the prescribed regimen, since the 
patient may be taking the drugs in another way than prescribed; either intentionally or 
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unconsciously. The pharmacist should therefore ideally interview every patient about 
their drug therapy by using open-ended questions, as this allows the patient to 
explain how and why each drug is used. If the patient have their own drugs (PODs) 
brought in with them, the patient can show the pharmacist how each of these are 
being used. As the patient may forget to mention inhalers, eye drops and injections 
and only list medicines in tablet form, the pharmacist should specifically ask if any 
such preparations are used. The patient may also omit to tell the pharmacist about 
herbal medicine or non-prescription medicines out of forgetfulness or because the 
patient don’t think this information is relevant to the pharmacist. 
 
If the pharmacist thinks it is helpful, an interview scheme can be used for taking drug 
history, as this may help the pharmacist remember to ask the patient all the relevant 
routine questions.   
 
 
Table 3 Questions to clarify the patient’s actual drug regimen 
Do you use: 
• All of the prescribed drugs? 
• Any herbal/alternative medication? 
• Any other drugs than those the doctor have prescribed for you? 
• Any vitamins? 
• Any inhalers, injections, topical ointments or eye drops? 
 
 
The pharmacist should respect and understand the patients need for privacy, and ask 
their questions in a discreet way. In an outpatient clinic discretion may be ensured by 
interviewing the patient in a private room, but if the patient meeting is situated in a 
hospital environment, discretion may be harder to ensure as most inpatients share 
rooms. Obviously some patients may think that questions about i.e. illicit drug use, 
laxatives and contraceptives is taboo and therefore hesitate answering them, but a 
patient may as well feel that the treatment of their diabetes treatment or use of 
painkillers is a private matter as well, and the level of discretion should therefore 
always be as high as possible.  
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Questions about the patients compliance should be asked in a non-judgemental way, 
as it is important that the patients feel that they can be honest with the pharmacist.  A 
question like “You do take all your medicines, right?”, is more leading than the 
question “Some patients think it is hard to remember to take all their medicine, do you 
sometimes feel this way?”. While the first questions tells the patients that the 
pharmacist expects them to answer that they always take all their medicines, the 
latter one opens up for the patient to feel more comfortable about telling the 
pharmacist about possible compliance problems. 
 
Table 4 Questions to clarify compliance 
• How do you take your medication? 
• When do you take your medication? 
• How often do you take your medication? 
• How much of the drug do you take? 
• Some patients think it is hard to remember to take all their medicine, do you 
sometimes feel this way? 
• Have you experienced any adverse events? 
 
 
By asking the patient these questions the pharmacist clarifies relevant drug history at 
the same time as the patient may reveal care issues regarding compliance, 
interactions between prescribed and herbal medicine or drug transcription 
discrepancies.  Once the drugs on admission have been clarified, the pharmacist can 
begin to verify the drugs prescribed at the hospital. 
 
A complete medication history will also contain information about social drug use; 
e.g. weekly alcohol consume and smoking status (never, ex-smoker or number of 
cigarettes per day). Excess alcohol can greatly affect the liver metabolism for a 
number of drugs, in addition to affecting the patient’s health in a number of ways.  
 
Allergy status should always be determined when a patient is transferred between 
care settings, as the patient may have been exposed to new drugs and reacted to 
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these in between settings. The pharmacist should ask the patient to describe the 
adverse events experienced, as it is important to differentiate between allergies, 
sensitivities and pseudo allergies. If a patient is sensitive to a drug, this is important 
information because the drug can potentially be used again if necessary, while a drug 
the patient have experienced a severe allergic reaction to never can be administered 
again. If a condition later should appear where a drug is indicated that the patient is 
sensitive to, they should be included in an evaluation of the benefits of taking the 
drug compared to the risks. Where it is relevant notes can be made about drugs that 
have been used earlier and which effect they had. For patients treated for e.g. manic 
depressive disorder several medication regimens may have been used to treat the 
patient previously, and details about the patients experiences with these would 




1.2.4 Presenting care issues 
 
The most important part of the pharmaceutical care plan is the section where the 
pharmaceutical care issues are presented. The issues should be presented in a  
concrete and concise manner, since this will make it clear what the patients care 
needs are. 
 
A care issue expressed as a desired outcome should be defined as precisely as 
possible, together with one or more identified actions. When the pharmacist 
describes an action to be undertaken, notes should also be made to explain if the 
pharmacist will take responsibility for solving the issue their self, or if it needs to be 
referred to another member of the pharmaceutical care team, e.g. the medical 
practitioner. It is also natural in most cases to state when a possible outcome may be 
expected/checked for, and this makes the basis for setting the review date for the 
issue. On the next review date the outcomes should be documented for all those 




Table 5 Presentation of care issue in a care plan 
Care issue/ 
Desired outcome 
Action Outcome Review 
date 
    
 
A scheme like this is used as a tool with the aid of helping the pharmacist to organise 
the care planning in a structured way. The idea behind splitting the issues into 
several parts is that this will make it easier for the pharmacist to see what the 
problem is and how it is planned to be addressed. The care plan has two functions, in 
addition to functioning as a tool for planning pharmaceutical care, it is the 
pharmacists primary documentation paper. The pharmacists should document their 
care giving to the same extent as doctors and nurses do, and the separate outcome 
box underlines the importance of this fact. 
 
 
1.2.5 Investigations and monitoring 
 
Monitoring is a cyclical process where the results from the monitoring determine the 
next step in the process of giving pharmaceutical care. An initial plan for 
management of the care issue is first made, where relevant indicators for monitoring 
should be specified. A good plan will include suggestions for management of 
probable scenarios and outcomes, and so the initial plan simply can be adjusted or 
modified according to changes in the patient’s condition. If something unexpected 
happens the plan might need to be revised in order to meet the patient’s new needs. 
 
Table 6 Relevant indicators to check when monitoring 
Indicators Examples 
Lab values Renal function, K+, FBC 
Effect CRP, fever, analgesic effect 
Side effects Platelets and dalteparin 
Drug titrated up ACE inhibitors, beta blockers 
Drug titrated down Steroids, opioids 
Drug stopped Antibiotics, steroid courses 
Change of administration form IV antibiotics to oral antibiotics 
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Table 6 (Cont) Relevant indicators to check when monitoring 
Suspended drug started again Furosemid and renal function 
Suspended drug stopped Bendroflumetiazide 
Interactions Theophylline and Erythromycine 




1.2.6 Transitional care planning 
 
Continuity of care is how individual patients experience coordination and integration 
of services. Discharge and transfer between wards can be viewed as gaps in the 
continuity of the patient’s care, that needs to be detected and bridged7. Transitional 
care is a term used to describe the efforts undertaken to bridge this gap, and has 
been defined as “a set of actions designed to ensure the co-ordination and continuity 
of health care as patients transfer between different locations or different levels of 
care in the same location”8 . When transferring a patient between hospital wards or 
discharging the patient, this implies that there must be established good routines that 
ensure collaboration between health care workers, and that all relevant information is 
transferred along with the patient.  
 
An early arrangement of continuity of care for discharge is important since the time 
for this can be difficult to plan. A discharge of an inpatient to primary care can be 
hastened by unexpected events; i.e. an other patients may have a greater need for 
the bed that the patient occupies, the patient may wish to leave on their own initiative 
and etc. Transfer of a patient between clinical settings may also be difficult to plan as 
a patient’s conditions may deteriorate or improve in another rate then expected. 
Some discharges are planned to take place at times where practical arrangements 
may be more difficult to organize, for instance during weekends. 
 
Before the patient leaves the hospital the patient should have been educated and 
have an understanding of how all the drugs works and how to take them. The 
National Prescribing Centre suggests in the guide “Modernising Medicines 
Management” that “services that enable patients to remain safe and independent in 
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their normal environment for as long as possible, may include improving patient 
education and awareness about medicines and/or support to carers”9. When the 
patient is discharged there may be a lot of things happening around the patient that 
can be distractive, in addition to that the fact that the patient gets to go home may be 
distractive in it self. Earlier during the hospital stay the patient will have more time to 
reflect on the information he/she gets, and if there are problems with understanding 
how to take the medication, the patient will have an opportunity to ask the ward staff 
about their medication use one more time. 
 
In a randomised controlled trial investigating the effects of providing patient education 
combined with an adherence aid, the results showed substantial and sustained  
improvements in  adherence as a long as this service was provided10. All the patients 
in the study were 65 years or older, lived independently and was taking at least four 
chronic medications daily. Some 91.5% of the patients had drug treated hypertension 
and 80.6% had drug treated hyperlipidaemia. There were 200 patients that entered 
the study and these were randomised into two groups; “usual care” or “intervention”, 
consisting of pharmacist provided education and follow-up every 2 months, in 
addition to the supply of custom blister-packed medication. After a two month run-in 
phase baseline adherence, systolic blood pressure and LDL-cholesterol was 
measured. The measurements was repeated 6 month after intervention to both 
groups, and then again 6 months after the patients was randomised into 
“intervention” and “usual care” groups.  
 
Table 7 Patient education study results 11 
 














Intervention Usual care 



















(CI -10.7 to -3.1) 
–1.0 







No differences No differences 
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This study does not say what effect the patient counselling or the adherence aid 
alone would have had, but makes it clear that the two of them together both 
increases adherence and thereby increases therapy outcome. This illustrates that 
there is a clear connection between poor adherence and low health benefits of 
pharmacotherapy. 
 
Another randomised study’s conclusion confirmed these findings, stating that “A 
pharmacist intervention for outpatients with heart failure can improve adherence to 
cardiovascular medications and decrease health care use and costs, but the benefit 
probably requires constant intervention because the effect dissipates when the 
intervention ceases”12. In this study 314 low-income patients aged 50 or older was 
randomised into 9 months of multilevel intervention followed by a 3 months post-
study phase, or “usual care” for 12 months. The patients in the intervention group 
were provided verbal and written instructions and were followed up every 2nd month. 
During the study period the pharmacists monitored medication use, health care 
encounters and body weight, and adherence was measured to be 78,8% in the 
intervention group versus 67,9% in the usual care group, but that this effect 
dissipated to respectively 70.6% and 66.7% after the intervention period. The 
researchers also found that emergency department visits and hospital admissions 
where 19.4% lower in the intervention group. 
 
These two studies shows the importance of preparing the patients for discharge from 
hospital by giving them proper education about their drugs, but also highlights the 
great health benefits the patient can experience when it is arranged for continuity of 
their care within primary health care services.  
 
The clinical pharmacist also has an important role in ensuring that the patient is 
prescribed the correct TTAs. A prospective cohort study published in 2003 reported 
that nearly 1/5 of patients experienced an adverse drug event (ADE) during transition 
from the hospital to home13. One third of these ADEs where evaluated to be 
preventable and another 1/3 to be ameliorable. The severities of these ADEs ranged 
from serious laboratory abnormalities to permanent disabilities, and were in part 
explained by ineffective communication between the ward staff and the GP as well as 
between ward staff and the patient. As a way of communicating better with the GP, it 
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was suggested that the discharge letter should contain specific information about 
what the follow-up physician needs to do, when they should do it, and what they 
should watch for. 
 
A UK survey of discharge prescriptions reported in 2002 that junior medical staff 
members where responsible for preparing virtually all discharge prescriptions, and 
that these where checked against the ward prescription charts by pharmacists in 
75% of UK Trusts14. Junior doctors are the least experienced of the medical 
practitioners when it comes to pharmacotherapy, and this may be one of the reasons 
why pharmacists write more accurate discharge prescriptions than doctors.  
 
 
1.3 Medicines management 
  
While pharmaceutical care is patient specific, medicines management (MM) applies 
to populations of patients as well as individuals. “Medicines Management 
encompasses all the activities that contribute to safe and rational medicines use, 
including strategic functions such as purchasing, formulary policy, risk management 
and many other roles of pharmacists and pharmacy technicians”15. 
 
 
“Medicines Management in hospitals encompasses the entire way that medicines are 
selected, procured, delivered, prescribed, administered and reviewed by to optimize 
the contribution that medicines makes to producing informed and desired outcomes 
of patient care”4. This means that the term medicines management includes a range 
of activities, from an individual medical review to a health promotion program. The 
superior emphasis for medicines management will anyhow be to optimise drug 
treatment for the individual patients, regardless of what the actions undertaken are.  
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The NHS groups Medicines Management services into 5  broad types9, 16;  
• Clinical MM is patient-centred and includes assessments, medicines 
monitoring and reviews of prescribing for individual patients.  
• MM systems and processes are used to, for instance, implement clinical 
governance and national guidance and policies. The aim is to make the best out of 
available resources, and an example of this is improving repeat prescribing. An audit 
is a tool, which the NHS the recent years has encouraged the NHS boards and 
organisations to undertake with the aim of implementing new guidelines. Special 
boards such as the National Prescribing Centre and the National Institute for Clinical 
Excellence (NICE) and also the Royal Pharmaceutical Society of Great Britain have 
published a lot of material describing how different NHS organisations and services 
can undertake audits. 
• Health of the public  MM Services are aimed at improving the health of the 
population as a whole. Examples of such services are disease prevention strategies 
like low dose aspirin for secondary prevention of heart attack, and services that 
target specific groups like smoking cessation. 
• Continuity of care. The NHS’ supplying of medicines for 28 days after 
discharge from hospital and the use formularies and guidelines across different care 
settings are examples of efforts undertaken to ensure continuity of care. 
• Patients and their medicines. Services may include  improving patient 
education and awareness about medicines, provision of support for carers and 






In this project a triangularised categorisation system was used to quantify care 
issues. The categorisation system was based on theory on: 
1. Drug Therapy Problems 
2. Check and Changes 
3. Quality Assurance Descriptors 
 
 30
1.4.1 Drug Therapy Problems 
 
Drug Therapy Problems are defined as “any undesirable event experienced by a 
patient which involves, or is suspected to involve, drug therapy, and that interferes 
with achieving the desired goals of therapy.”5 
 
Theory about Drug Related Problems (DRPs) were first presented by Strand et al. in 
199017, but this terminology where later changed by Strand, Morley and Cipolle to 
Drug Therapy Problems (DTPs), as presented in the book “Pharmaceutical Care 
Practice – the Clinician’s Guide”5. The terminology and theory behind DTPs is well 
known in clinical pharmacy research environments, and the categorisation system is 
well tried out in practical use. 
 
Drug Therapy Problems consists of 7 categories, and all of these are further divided 
into subcategories. 
 
Table 8 Categories and common causes of drug therapy problems 
Drug Therapy 
Problem 
















There is no valid medical indication for the drug therapy at this time 
 
Multiple drug products are being used for a condition that requires single drug 
therapy 
 
The medical condition is more appropriately treated with non drug therapy 
 
Drug therapy is being taken to treat an avoidable adverse reaction associated 
with another medication 
 
Drug abuse, alcohol use, or smoking is causing the problem 
 









A medical condition requires the initiation of drug therapy 
 
Preventive drug therapy is required to reduce the risk of developing a new 
condition 
 
A medical condition requires additional pharmacotherapy to attain synergistic 
or additive effects 
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The drug is not the most effective for the medical problem 
 
The medical condition is refractory to the drug product 
 
The dosage form of the drug product is inappropriate 
 
The drug product is not an effective product for the indication being treated 
 









The dose is too low to produce the desired response 
 
The dosage interval is too infrequent to produce the desired response 
 
A drug interaction reduces the amount of active drug available 
 















The drug product causes an undesirable reaction that is not dose-related 
 
A safer drug product is required due to risk factors 
 
A drug interaction causes an undesirable reaction that is not dose-related  
 
The dosage regimen was administered or changed too rapidly 
 
The drug product causes an allergic reaction 
 
The drug product is contraindicated due to risk factors 
 











Dose is too high 
 
The dosing frequency is too short 
 
The duration of drug therapy is too long 
 
A drug interaction occurs resulting in a toxic reaction to the drug product 
 















The patient does not understand the instructions 
 
The patient prefers not to take the medication 
 
The patient forgets to take the medication 
 
The drug product is too expensive for the patient 
 
The patient cannot swallow or self-administer the drug product appropriately 
 




DTP categories describe both potential risks for the patient to develop medical 
conditions and actual events that the patient has experienced. A potential risk may be 
non-compliance, even though non-compliance is defined as a actual DTP, this DTP 
per se does not always lead to an event that deteriorate the patients health. For 
 32
instance if the patient have hypercholesterolemia but have problems remembering to 
take their daily simvastatin, this may or may not contribute to a subsequent 
development of a cardiovascular event. However, the repeated omission of doses 
inflicts a risk to the patient, and can therefore be identified as a DTP. In another 
scenarios the patient may present with urinary tract for which Nitrofurantion 50 mg x 3 
for a week is started, but at the end of the week the patient’s condition has not 
improved. The DTP in this scenario may for instance be non-compliance due to the 
drug product’s emetic effect or that the medical condition is refractory to the drug 
product. Anyhow the DTP will describe the reason for an actual event that the patient 
is experiencing, namely that the medical condition that hasn’t improved.  
 
1.4.2 Check and Change 
 
The theory on Check and Change is developed by Strand and McAnaw, and build on 
the Drug Therapy Problems. The Check category describes the checks the 
pharmacist undertakes in order to identify the DTPs, while the changes describes 
actions undertaken aiming to resolve the DTPs. The following table is presented in 
McAnaw’s doctor thesis18: 
 
Table 9 Pharmaceutical Care Issues and Drug Therapy Problems 
Checks: 









Modification need inquiry 
 
 
Additional medication needs 











Ineffective drug prescribed 
Dose too low (sub-optimum) 
Documentation (Patient Data Set): 
 
History 








Compliance inquiry  
 
 
Adverse drug reaction 







Daily (total) dose 
Route/dose form 
Dose interval/timing/duration 





All drug therapy problems are identified through checks and investigations 
undertaken/initiated by the pharmacist or other members of the pharmaceutical care 
team, except for those issues that the patient without being asked present 
themselves.  
 
The four categories of checks are directly linked to DTP categories5, implying that a 
check of for instance safety, more precisely is a check for adverse drug reactions 
and/or too high dosage.  
 
When a DTP is identified, one or more changes may be necessary to carry out in 
order to resolve it. For instance, if the patient experiences a severe adverse drug 
reaction, the drug needs to be stopped and the patients characteristics updated. If the 
patient have a compliance problem, education may be an suitable action in addition to 
changing the dose interval or route.  
 
The check and the change categories have been used for categorisation previously. 
In a study on pharmaceutical care documentation at a cancer centre, 430 care issues 




1.4.3 Quality Assurance Descriptors 
 
Quality Assurance Descriptors (QA Descriptors) build on the “Check and Change” 
system, and describe the ongoing process of providing pharmaceutical care. The 
theory on QA Descriptors is developed at the University of Strathclyde by McAnaw 
and Hudson3, 18. 
 
This model explains how pharmaceutical care can be provided according to a 
therapeutic plan; “the provision of quality assurance relies on the documentation of in-
process monitoring activity and checks in the assessment of the quality of the product 
(therapeutic plan)”18.   
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Pharmaceutical care planning is here regarded as a cyclical process which can be 
described in a quality system feedback loop. The following figure3 illustrates this 
quality system feedback loop. 
 
Expectations 




















Figure 1 The Quality Assurance Feedback loop 
 
 
Table 10 Explenations of the numbers in figure 1 
Pharmaceutical Care Profile 
Distribution of Changes 
 
1 Modify an initial design 
2 Adjust an initial design 
3 Adjust during monitoring 
4 Modify after evaluation 





There are three degrees of changes that can be undertaken in the feedback loop3: 
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1. Adjustment is defined as a recommended change to the patients behaviour, 
treatment regimen or continuity of care that individualises pharmaceutical care 
within the agreed treatment plan 
2. Prompting a review which is defined as a complete review of the initial treatment 
plan 
3. Modification which is any recommended change other than adjustments and 
reviews. 
 
When drug therapy is initiated and a treatment plan started, the pharmacist will 
undertake a number of checks in order to verify the prescribed drug regime. At the 
point of verification a need to adjust or modify the treatment plan may be identified. As 
the treatment continues, the delivery of the treatment plan will be monitored, and the 
plan may once again be subject to adjustments or modifications. An evaluation is 
done at the end of the treatment to confirm either that the predefined expectation have 
been met, or that the treatment have failed to meet them. A confirmation may result in 
a review or modification of the treatment. A pharmacist will be able to suggest 
changes that are adjustments and modifications alone, but will not be able to perform 
a review on their own; it can only be prompted by the pharmacist, and that is the 
reason why this category is called prompting review. 
 
 
Table 11 Categorisation of checks according to quality system feedback loop3 








Checks to make sure that for each medicine, the patient: 
Is on the right medicine 
Is on the right dose 
Is not on unnecessary medication 
Doesn’t have any new needs for additional medication 
Is not receiving a combination of interacting medicines 
Understands how to take their medication and what it    
will do to them 
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Table 14 (Cont.) Categorisation of checks according to quality system feedback loop3 






checking for safety and 
effectiveness 
 
Checks should ensure that, for each medicine, the patient: 
Is on receiving medication as intended 
Continues to be on the most suitable dose 
Has no symptoms of unwanted (adverse) effects 
Understands how to take their medication 







Confirmation and documentation to identify that medication 
is: 
Resulting in expected effects on the patient's condition
Not failing to control condition 
Not producing unwanted effects requiring clinical   
review. 
 
The checks in the QA Descriptor system are the same as those presented in section 
1.4.2; Medication need, Effectiveness, Safety and Compliance. 
 
 
Table 12 Categorisation of changes according to quality system feedback loop3 
Changes recommended at the Start of Treatment 
 
Modification/ 




Changes recommended to address initial inappropriateness to 
ensure the patient: 
Is on appropriate medication 
Is on appropriate medication regimen 
Has all needs for medication addressed 
Has the necessary understanding of how to take their  
medication and what it will do to them 
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Table 13 Categorisation of changes according to quality system feedback loop3 
As treatment Continues 
 
Modification/ 




Changes recommended should ensure that  any necessary 
individualisation is implemented so that the patient have their: 
Dose adjusted according to the treatment plan 
Medicine choice changed if it is a part of the initial  
treatment plan 
Education reinforced about their medication and their  
condition 
Continuity of care maintained 
 
After a period of a Course of Treatment 
 
Prompting a 
review of the initial 
treatment plan 
 
Changes recommended as a result of a review of the 
treatment plan by the health care team: 
Dose changes outside the initial treatment plan 
Choice of medication outside the initial treatment plan 
New requirements for patient monitoring outside the initial  




1.5 Electronic prescribing 
 
The use of computer technology could significantly reduce the number of prescription 
errors, which cost the NHS £1/2 billion each year in longer stays in hospital4.  From 
2003-2006 the NHS prioritised £ 6.2 billions on the IT programme “Connecting for 
Health”, and are with that encouraging hospitals to implement electronic prescribing 
and medicines administration systems (EPMA)20. The original deadline for 
implementing electronic prescribing and electronic patient records was 200521, but this 







1.5.1 Electronic prescribing at The Ayr Hospital 
 
An electronic prescribing system has been established at the Ayr Hospital (TAH) since 
1997. The electronic prescribing system used at TAH is called Prescription Order 
Entry (POE) and is a part of the hospitals electronic filing system delivered by JAC 
Computer Services Ltd (previously delivered by Pharmakon UK, both companies now 
owned by Mediware). 
 
TAH is the only hospital in Scotland and one of few in the UK, which have a fully 
computerised electronic prescribing and medicines administration system (EPMA). A 
survey conducted in 188 UK hospitals in 2000 found that only 2% of the hospitals 
have full electronic prescribing facilities22. Today 5 hospitals in the UK use JAC’s 
software for electronic prescribing and medication administering23.  
 
A study evaluating of the EPMA system used at TAH has shown that it is at least as 
safe or safer than the previous paper-based system 22, 24.  The study was conducted 
at TAH between February 1998 and July 1999, and evaluated the implementation of 
an EPA system at an orthopaedic ward with 36 beds. The study compared rates of 
prescribing errors for inpatient prescriptions and discharge prescriptions, and also 
rates for medication administration errors. Rates were measured when the existing 
paper-based prescribing system was used, one month after the implementation of the 
EPMA system, and 12 months after implementation. 
 
Table 14 Frequency of prescribing and medication administration errors 
 Prescribing errors  

















































































After the implementation of the EPA system, the inpatient prescribing error rate fell 
from 7.4% to 4.7% over 12 months (p<0.001). The discharge prescription error rate 
initially increased from 7.5% to 7.7% and then dropped to 5.9%, but these numbers 
were not significant. There was a reduction in administration errors, with a decrease 
from 9.0% to 5.4% over 12 months (p<0.001), but these numbers were biased since 
IV drugs and controlled drugs was not included. 
 
TAH has been one of the pilot sites for use of electronic prescribing, and the system is 
now well established. Throughout the hospital wards laptops are connected to the 
EPMA system via a wireless internet connection. The laptops are attached to trolleys 
and are moved around by the medical team on the ward rounds, and this makes the 
EPMA system an electronic, portable drug chart. Even though the doctors can 
prescribe drugs through EPMA system from any location at the hospital, they tend not 
to. Most of the prescribing is still done during the ward rounds, based on decisions 
undertaken there. The medical records at TAH are paper based and located outside 
the patient rooms, and it is therefore convenient for the doctors to prescribe drugs at 
this site, also at other times than during the ward round. 
 
Laptops are also attached to the drug trolleys, and the nurses therefore have access 
to EPMA at the bed site which facilitates that administration can be documented at the 
same time as it is done. It is important that drug administration is documented 
accurately with moment times, especially when blood samples for through and peak 
concentration are drawn, and when IV antibiotics are given. Easy access to EPMA 
ensures that prescribing and administering of drugs can be done and documented the 
same way as with paper based drug charts. 
 
Laboratory results and X-rays are also available electronically within the filing system, 
while all other patient records and notes are paper based. Due to convenience, INR 
results and prescribed warfarin dosages, as well as monitoring of blood glucose levels 
and prescribed insulin dosages, dosing regimens for infusions and etc. are kept 




1.5.2 Advantages and disadvantages with electronic prescribing systems 
 
The main advantages with Electronic prescribing systems (EPS) are that they reduce 
medication and transcription error rate25 due to elimination of illegible hand written 
prescriptions and interpretations of these. The EPS facilitates a more structured way 
of writing drug prescriptions, ensuring that dosing regimens and administration routes 
are clearly stated in addition to the drug name it self. However, when the prescriber 
writes the drug name into the EPS, available formularies and doses gets available for 
selection, which can lead to juxtaposition errors. For the prescriber it generally also 
takes longer time to write separate prescriptions in an EPS than on a paper chart, 
while functions like ordered prescribing sets saves time for the prescriber. Electronic 
prescribing and administration (EPA)  systems also provide a full and accurate 
medication history for the patient in the clinical setting. With the introduction of 
electronic prescribing and medicines administration documentation it is also easier to 
identify doctors, nurses and pharmacists within the system. A pharmacist verification 
function within the prescription system helps to streamline the pharmacist’s work in 
terms of the prescription verification process. 
 
The new screen interface can lead to a loss of overview in the prescribing process, 
since the prescriber can’t see the other drugs the patient is on when the prescribing 
window is open. At a paper chart  it is possible to view the whole chart 
simultaneously, while the EPS can fragment information for drug regimens consisting 
of several drugs, due to a fixed interface size. The users of such systems therefore 
have to adapt to a new way of writing and reading information.  
 
Electronic prescribing opens for the possibility of connecting a range of support 
services directly to the prescribing process, which further can reduce the error rates. 
A decision support system is pro-active and alerts the prescriber with pop-up boxes 
when drugs are prescribed. Like there are several EPA systems on the marked, there 
are several support systems, and these may include:  
 
• drug-drug interactions checks 
• drug class duplication checks 
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• allergy checks 
• Information about cautions/contraindications 
• Dose checking against patient parameters such as age and weight 
• Formulary/prescribing status 
• Monitoring warnings 
 
A support system will also give access to updated monographs 
 
Even though the alerts are intended to attain the prescriber’s attention, their effect will 
be limited by the prescribers acceptance and willingness to use the system, alerts can 
be ignored. A survey of the clinical relevance of automated drug alerts among primary 
care providers, demonstrated a wide variance in the perceived usefulness of decision 
support systems. Generally the prescribers had the opinion that duplication alerts had 
low utility, while drug interaction alerts were perceived to have a high utility26.  
With electronic prescribing data are immediately available and the job of gathering 
prescription data for  analysis and audits takes is simplified. Data gathered 
electronically will be reliable and of easy access, as long as ethical approval for their 
use is obtained. 
 
Medication ordering errors are the largest identified source of preventable hospital 
medication errors27. While electronic prescribing reduces the rates of some errors, it 
also creates new types of errors; a study published in 2005 reported 22 new types of 
medication error risks27. There were two main types of errors: 
 
1. Information errors generated by fragmentation of data and failure to integrate 
computer and information. 
2. Flaws in the interface between human-machine, reflecting that a machine 
operates by rules that not can be manipulated. 
 
The prescribing system used in this study is not the same as that used at TAH, and 
some of the faults found with the system in this study will not relate to  POE which is 
used at TAH. Generally type 1 faults involved that hospital staff lacked adequate 
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information about the use of the EPS, or that the system was not practical for to use 
under all circumstances. Examples of type 2 faults are: 
 
• Wrong patient selection 
• Wrong medication selection 
• Loss of data, time and focus when the prescribing system were non-functional 
due to computer crash or maintenance work 
 
 
1.6 Clinical Setting 
 
1.6.1 The medical cardiology ward 
 
The medical cardiology ward at TAH has a capacity of maximum 24 patients and 
usually all bed sites are occupied, with 3-4 new patients entering the ward every day. 
The patients generally are admitted from primary care on planned admissions, or they 
are transferred from the coronary care unit or the medical receiving ward after 
emergency admissions to the hospital. This means that many of the patients at the 
medical cardiology ward already have a pharmaceutical care plan started for them 
when they transfer to the ward, and that the GPs prescriptions already are transcribed 
over to the EPMA system and verified by a pharmacist together with some of the 
drugs prescribed at the hospital.  
 
There are one shared female and two shared male bed rooms with 6 beds each, and 
six single bed rooms at the ward, and this is reflecting that more men than women is 
admitted to the ward, and that more men than women suffers from cardiovascular 
diseases. The patients on the ward primarily have cardiac/cardiovascular disorders, 
however they will inevitably have other co-morbidities. If the pressure to accept 
patients at TAH is high, some of the patients at the ward may present with a wide 
range of other non-cardiovascular medical problems. Two pharmacists, MC and KW, 
work every other week at the cardiology ward. No pharmacists work at the ward on 
Saturdays or Sundays, but there is a clinical pharmacist on call on Saturday mornings 
that can be called by the ward if needed. Since the patients with the worst conditions 
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are admitted elsewhere, to the Coronary Care Unit, it rarely happens that there is a 
need for a pharmacist at the cardiology ward in the weekends. 
 
 
1.6.3 The Coronary Care Unit 
 
The Coronary Care Unit is a high care unit for patients with severe cardiac conditions. 
Patients are generally transferred to this unit from the accident and emergency unit 
after acute incidents, or from the medical cardiology ward after complications to their 
condition. One pharmacist, GJ, usually covers the ward during the weekdays and in 
addition an “on call pharmacist” can be contacted Saturday mornings. The unit has 
four single rooms and one double room, and the number of admitted patients varies 
from as low as two to six patients. As this is a high care unit patients will be 
transferred to another ward when their condition is improving, since this will make 
their bed site ready for another emergency patient. 
 
 
1.7 Delivering pharmaceutical care at the medical cardiology ward 
and the Coronary Care Unit 
 
A table over how much time the pharmacists at the medical cardiology ward spends 
on the pharmaceutical care processes can be found in appendix 1. Process maps 
showing the provision of pharmaceutical care can be found in section 1.8 Process 
maps. 
 
For the pharmacist working at the Coronary Care Unit it is not a problem to have an 
overview of the patients admitted and their pharmaceutical needs, but at the medical 
cardiology ward where the patient number is higher the pharmacists need to plan how 
they best can spend their time. While all patients at the Coronary Care Unit generally 
needs to have their pharmaceutical care plans reviewed daily, some patients at the 
medical cardiology ward may need to be followed up less frequently. The pharmacists 
therefore have a system they use for identifying who patients they will see that day. 
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Every morning the pharmacist identifies patients newly admitted to the ward by 
looking at the daily bed state located at the ward, or by printing a list from the 
electronically available HIS System (Hospital Information Support System). The 
pharmacist will subsequently start the day by seeing all new patients and initiate a 
pharmaceutical care plan where this is needed.  
 
From the electronic prescribing system another list that shows which patients’ care 
plans that are to be reviewed can be printed, and the pharmacist will see through 
these patients clinical notes and provide them with pharmaceutical care during the 
day.  
 
An issue generator program called “Crystal Reports” can be asked to find unverified 
orders, drugs that needs to be monitored like amino glycosides and digoxin and etc. 
The pharmacists will routinely check for unverified drugs, but rarely use the issue 
generator for other tasks at these wards. The pharmacist will by checking for 
unverified orders capture changes made to all patients drug treatment, and not only 
those that have a review date on that particular day. 
 
The pharmacists at the medical cardiology ward don’t attend the morning ward 
rounds, but still have good communication with the medical staff since they spend 
most of their available time at the ward. If the pharmacist wants to discuss a care 
issue with a member of the medical staff, a junior doctor will be first be contacted. If 
the issue doesn’t get sorted by this and the pharmacist disagrees with the junior 
doctor, a senior doctor or the consultant at the ward will be contacted. 
 
 
1.7.1 Taking drug history and medical history  
 
A considerable part of the pharmacists’ time are spent on ensuring a correct drug 
history. The pharmacists at the cardiology ward use 15 – 20 minutes per newly 
admitted patient on reviewing medical records, taking medication history, clarifying 
current drug regime and allergies and initiating the pharmaceutical care plan.  
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When a new patient is admitted or transferred to the medical cardiology ward or the 
Coronary Care Unit, the pharmacist first checks if a care plan already have been 
started for him/her. If a care plan is started this means that the patient already has 
been seen by another pharmacist, and that relevant drug- and medical history have 
been taken and that drugs on admittance have been verified. 
 
If the patient hasn’t been seen by a pharmacist yet, the pharmacist at the ward will 
first read the patient’s medical notes to clarify relevant medical history. This gives the 
pharmacist an overview of the patient’s medical condition and the indications for drug 
treatment. Once this is done the pharmacist begins to clarify the patient’s current drug 
regime (drugs on admittance) and if the patient has any allergies.  The pharmacist 
tries to get the drug history confirmed with more than one source if possible, but this 
isn’t regarded as necessary if the pharmacist thinks that the patient has good 
knowledge about his/her drug regime. Patient’s own drugs (PODs) are not used at the 
medical cardiology ward or the coronary care unit. 
 
Since the patients’ drug regimens are available together with the pharmaceutical care 
plan in the electronic prescribing system; POE, there is no need for the pharmacist to 
list dosing regimes for any drugs except insulin and warfarin and some drugs for 
infusion in the care plan. Even though dosing regimes generally not are listed in the 
pharmaceutical care plan, the pharmacist will list deviations of drugs on admittance, 
as a part of the documentation process when verifying drugs. 
  
 
1.7.2  Transcription and verification 
 
Clinical pharmacists that have their approval from the chief clinical pharmacist, are 
allowed to transcribe drugs prescribed by the patient’s GP/doctors outside TAH. Both 
pharmacists and nurses are allowed to transcribe drugs in addition to doctors. To 
transcribe a drug means to make an exact copy of a prescription made by a doctor, 
and the transcribed prescription is therefore regarded as equally valid as a 
prescription issued at the hospital by one of the doctors there. By transcribing and 
verifying prescriptions such as these, unnecessary brakes in the patients medicinal 
treatment can be avoided, which ensures that the patient’s pharmaceutical care is 
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continued at the hospital. Pharmacists are also allowed to transcribe prescriptions 
made in the patients medical notes on to the EPMA system, or transcribe changes in 
doses and etc according to the patients treatment plan. This means that the  
pharmacist can both start and stop drugs as long as it is documented in the patients 
medical notes that this should be done. 
 
As a part of the prescribing quality and control system at TAH, the pharmacists are 
routinely verifying most drugs that are transcribed and newly prescribed, and the 
pharmacists spend 10–15 minutes per patient on doing this. The pharmacists will 
check the appropriateness of each drug regimens and evaluate if the drugs should be 
verified and/or transcribed to  the hospitals electronic prescribing system (EPS).  
 
If the pharmacist thinks that any prescriptions are inappropriate they will withhold the 
verification for it, or in severe cases suspend the drug. Since the pharmacists at the 
TAH aren’t authorised to prescribe drugs, they principally can’t suspend them either, 
but on rare occasions they nevertheless will do so if they think the drug can harm the 
patient and are unable to get a doctor to stop or suspend the drug. When a drug 
verification is withheld the reason for this will be documented in the pharmaceutical 
care plan by the clinical pharmacists, and the pharmacist will also discuss the reason 
for the withholding with a ward doctor to get it sorted. 
 
While verifying the prescriptions, the pharmacist also evaluates the drug regime as a 
whole, and checks if any additional drugs should be transcribed/prescribed or if any 
drugs needs to be monitored and etc. 
 
 
1.7.3 The pharmaceutical care plan in use at the present 
 
The prescribing system in use at TAH, POE, have one big weakness, it does not 
contain a template for an electronic pharmaceutical care plan to be saved together 
with the prescribing data. The pharmacists in stead writes care plans in free text in an 
interface intentionally made for writing notes to the clinical pharmacist. The 
pharmacists could have used a paper based care plan with a structured template, but 
the pharmacy department have evaluated that the advantages with saving the care 
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plan electronically in POE, is greater than the disadvantages with working without a 
care plan template. An electronic care plan will never be lost and it will follow the 
patient between wards which helps to maintain the pharmaceutical care process. 
 
When a new PCP is initiated the pharmacist presents the patient and his/hers medical 
condition by listing presenting complaints (PC), past medical history (PMH), drug 
history (DH), drug allergies and laboratory results. The pharmacists writes these 
same headlines every time a care plan is started, as a way of structuring and unifying 
the documentation process between them selves. They further systemise the care 
plan by marking outstanding care issues with a star, and then remove it when the 
issue have been sorted out. Examples of pharmaceutical care plans are attached in 





The pharmacists at the medical cardiology ward uses 1-1 ½ hours per day on 
reviewing patients care plans and identifying new care issues where a care plan 
already have been started. 
 
 
1.7.5 Discharge planning and continuity of care 
 
The pharmacists at the medical cardiology ward uses 5 minutes per patient or 30 – 40 
minutes per day on providing patient education, and 5 minutes per patient or 15 – 30 
minutes per day on arranging for continuity of care. 
 
 
1.7.6 The discharge process  
 
When a patient is ready for discharge the doctor (usually a junior doctor) writes a 
discharge letter within the electronic prescribing system POE. The discharge letter 
includes a short résumé of the patient’s presenting complaints and results from 
patient examinations, a list of changes to the drug regime with information to the GP 
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about dose titration, why drugs are stopped and etc. If the patient needs any drugs for 
discharge the doctor prescribes TTA drugs (To Take Away) together with the 
discharge letter in the EPMA system, and sends the letter electronically down to the 
dispensary. If the patient doesn’t need any TTAs the discharge letter is faxed directly 
to the GP/primary care setting. When the doctor prescribes TTA drugs, a list with all 
the patient’s active prescriptions will appear as a pop up for the doctor to make a 
selection from. The doctor can easily make changes to the patient’s drug regime, and 
prescribe additional drugs or discontinue drugs that no longer are indicated. The list 
over active prescriptions will include PRN medication, suspended and withheld drugs, 
and this may be a source for errors since a tick at a suspended drug is all it takes to 
prescribe it in error for discharge. An advantage with this system is that it ensures that 
a specific drug is continued in the same formulation, dose and dosing interval as last 
prescribed at the hospital, which will give fewer errors as long as it is desired that the 
patient continues to use the drug the same way as it was last prescribed.  
 
The pharmacists at the medical cardiology ward and the coronary care unit rarely 
verify TTAs or review the discharge letter, and the discharge process today is 
therefore not optimal. However, at the moment there is a project at the medical 
cardiology ward where the pharmacist writes the discharge letter and prescribes the 
TTA prescriptions. Since the clinical pharmacist at the ward knows the patient better 
than the pharmacists at the dispensary, the clinical pharmacist should ideally verify 
the drugs for discharge. The clinical pharmacist should also ideally review the 
discharge letter and check that all relevant information regarding changes in drug 
therapy and drug management is included in the letter. The clinical pharmacists in 
stead writes in the care plan what the pharmacist at the dispensary should check for 
regarding discharge. Since not all patients get TTAs, the discharge letter is not 
reviewed by a pharmacist for all patients. The clinical pharmacist writes information 
regarding discharge in the medical records if it is not feasible to speak with the doctor 
in person. 
 
1.7.7 The dispensing pharmacists 
 
When the patient needs drugs for discharge and the discharge letter containing TTA 
prescriptions is sent to the dispensary, the pharmacist here will verify this if it haven’t 
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been done already. The pharmacist at the dispensary will then read both the 
discharge letter and the pharmaceutical care plan for the patient, and if the 
pharmacist doesn’t think any changes needs to be made, the TTA drugs are 
dispensed according to the prescription. If minor interventions have to be made the 
pharmacist will simply document that the necessary changes are done on the paper 
print of the discharge letter, and dispense the drugs with interventions. For instance, 
according to a local policy no patients will ordinarily get PRN (as required) drugs like 
hypnotics to take home, and the dispensary will therefore not supply this for 
discharge. Since patients can get up to 28 days supply of TTA drugs at the hospitals 
charge, the POE will suggest that all drugs are prescribed for 28 days. The 
pharmacist therefore often changes antibiotics, steroids and other short term courses 
according to information from the discharge letter or the pharmaceutical care plan. If 
the patient uses a blister pack at home, one week of medication will be supplied. 
Minor changes like these will not be documented in the care plan. 
 
If anything regarding the TTA prescriptions is unclear or if the pharmacist thinks that 
greater changes needs to be made to the prescription, the discharge doctor will be 
called and the issue discussed. If the issue is complex the clinical pharmacist may be 
called and asked to contact the discharge doctor, since the clinical pharmacist have 
greater knowledge of the patient’s case and also more time to sort out care issues. If 
the doctor is contacted, this usually will be noted in the pharmaceutical care plan as 
well as on the paper print of the discharge letter. With today’s discharge process the 
pharmacists at the dispensary do most of the quality assurance of the TTA and the 
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Figure 4 Monitoring as a part of pharmaceutical care at the medical cardiology ward and 








Figure 5 Process discharge map at the medical cardiology ward and coronary care unit 
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1.9 Non-medical prescribing 
 
Many of the clinical pharmacists that work at the Ayr Hospital today are trained and 
registered with the Royal Pharmaceutical Society of Great Britain (RPSGB) as 
supplementary prescribers. However, the local policy at TAH says that the 
pharmacists only can practice their supplementary prescribing at the hospital’s clinics, 
and not at the wards. There are no plans to change this policy in the near future, but if 
or when the policy opens for pharmacist supplementary prescribing at the wards, it is 
essential to have a good routines for documenting this practice. 
 
It was the Health and Social Care Act of 2001 that opened for pharmacist 
prescribing28, and the first pharmacist supplementary prescriber (PSP) in the UK 
started prescribing in March 200429, while the first pharmacist independent prescriber 
(PIP) started in 200730. In May 2007 there were 34 supplementary training 
programmes accredited by the society in the UK, whereby two of these where in 
Scotland31. It is a local decision to train pharmacist prescribers, and where this is 
considered it is recommended by the RPSGB that in advance there is established a 
prescribing partnership with a medical practitioner, and that the pharmacist have at 
least two years of appropriate patient oriented experience. To become a pharmacist 
independent prescriber the pharmacist can take either a conversion course that takes 
the supplementary course a step further, or an independent prescriber programme, 
which last the equivalent of 28 days over three to six months.  
 
A pharmacist supplementary prescriber can prescribe licensed, unlicensed and 
controlled drugs after a written treatment plan agreed upon by the medical prescriber, 
the pharmacist and the patient. A PIP can only prescribe licensed drugs 
independently, but since PIP also can prescribe supplementary through an 
established prescribing partnership, unlicensed and controlled drugs can be 
prescribed where there is a written treatment plan regarding these drugs. 
 
Together with Patient Group Directions and Over the counter sales there are now 4 
major routes by which the pharmacist and other medical and non-medical prescribers 
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can supply a patient with drugs. For each of these routes it applies that they should 
only be used where the benefit to the patients are clear32: 
 
• Improved patient convenience 
• Increased equality 
• Maximised use of scarce resources and flexibility of workforce 
• Increased quality of care 
• Value for money 
• Reduced waste 
 
 
1.10 Qualitative research 
 
Qualitative research describes how and/or why something is done. In descriptive 
surveys the aim is to communicate to outsiders an accurate and detailed process or 
action, but also why a process is done in the observed manner. Later on observations 
from the survey can be used to evaluate how things can be done in another way.  The 
researcher will take different approaches in a quantitative survey and a qualitative 
one. Once the survey instruments have been developed in a quantitative survey, the 
data collection, processing and analysis will become to some extent administrative 
tasks. In qualitative surveys however, the researcher must remain sensitive to the 
responders’ viewpoints and be prepared to consider new issues and ask questions 
throughout data collection and analysis 33. 
 
 
1.10.1 Clinical audit 
 
An audit is defined by the Royal Pharmaceutical Society as “Improving the care of 
patients by looking at what you are doing, learning from it and, if necessary, changing 
practice” 34. 
 
Hence an audit is a part of health care workers quality assurance. A clinical audit is a 
systematic approach aiming to optimise a process or a treatment, and must not be 
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mistaken as research where a hypothesis will be tested. A thematic review of a 
particular part of patients’ medical treatment will be undertaken, for instance how well 
discharge information about a patient's medication is transferred to the community 
pharmacist, or the pharmacist's role in smoking cessation. In this clinical audit the 
pharmacist documentation of pharmaceutical care is evaluated.  
 
 
1.10.2 Action research 
 
The action research approach used in this project consisted of an audit design cycle 
and an evaluation and validation of data in a focus group meeting. An audit design is 
a cyclical process, consisting of reviewing and monitoring current practice and 
evaluation against agreed predefined standards 33. This cyclical design allows service 
evaluation to be done continuously through the survey, and describes how 
pharmaceutical care is provided at the same time as it aims to improve it. 
 
Focus groups are a qualitative research tool used to ensure content validity in 
descriptive studies. They are employed to make sure that all factors regarded as 
important by the population (here the pharmacists at the Ayr Hospital) are taken into 
consideration, and not just the ones discovered by the investigator. A focus group can 
correct and supplement the information and the comprehensions the investigator 
have, and strengthen the validity of the content in this manner. 
 
A facilitator or moderator will lead the focus groups and aim to ensure that all topics 
agreed upon prior to the focus group meeting are discussed. The facilitator should 
also encourage that all the group members participate in the discussion, by giving the 
participants enough time to discuss each topic adequately, and by asking open 
questions that invite members to contribute with their view on the topic. If all the 
participants have felt that they have been able to express their opinions and that they 
have been heard, the focus group as a research tool can be regarded as valid. Ideally 
the participants will be given time before the focus group to reflect on the agreed 
topics, and one or more group meetings before the focus group will also contribute to 
increased validity for the findings in the final focus group. 
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A co-facilitator will be responsible for recording who states what in the group, as it is 
important the be aware of any group member(s) that may have been dominating the 
others through out the discussion. Dominant participants may lead to bias of the 
conclusions made by the focus group, as the content and findings should reflect the 
hole group’s view points. The group discussion should be tape recorded, in order to 









To review two cohorts of patients in terms of pharmaceutical care delivered by 
examining free text electronic records and categorising care issues into a proposed 
reporting system. To test the validity and the utility of the reporting system, by using 
qualitative research methods in an action research process. To propose a template 
for an electronic pharmaceutical care plan that meets defined criteria for service 




Review the literature on cardiology, the application of electronic health records; and 
the documentation of clinical pharmacy activities to inpatients and at the point of 
discharge from hospital. The usage of a pharmaceutical care issue categorisation 
system will also be a focus in the review as will be the introduction in the UK of non-
medical prescribing. 
 
To describe the operational delivery of the clinical service using a process map that 
is validated by pharmacists involved in care delivery.   
 
Identify documented care plans from samples of patients receiving pharmaceutical 
care during January 2008 to March 2008 using the electronic care monitoring 
system. Identify context and outcomes of each care plan by obtaining additional 
information from paper case records and through dialogue with clinical pharmacist 
authors to overcome any gaps in the free text electronic records. 
 
Modify existing categorisation system used at University of Strathclyde to increase 
the robustness and clinical usefulness. Develop a guideline for use of the system.  
 
Test utility and validity of the modified system.  
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Conduct a content analysis in a formal survey of the care plans in order to categorise 
the care issues.  
 
Demonstrate inter-rater reliability in the categorisation of the care issues in the 
survey.  
 
Evaluate proposed templates in terms of validity and utility for reporting care plans 
using an action research approach. Survey findings will be reported to the clinical 
pharmacy team over a series of meetings, in order to revise the template in response 
to the feedback obtained. 
 
Draw conclusions on the role of the audit findings in defining future application of 






The project was designed as a prospective, clinical audit of documentation of 
pharmaceutical care and the distribution of care issues in two different settings. The 
investigator and a co-investigator gathered data from one setting each by using an action 
research approach. All patients that received pharmaceutical care during the inclusion 
period in the two populations, were asked to give consent for the use of their medical 
notes. Patients that were unable to or declined to give their consent were excluded from 
the project. 
 
A guideline for a categorisation system was developed, and the data was 
subsequently subject to content analysis by this categorisation system. All results 
were evaluated in a focus group. 
 
3.1 Pilot phase 
 
The investigator trained on making standardised care plans in the period from 
October to December 2007, together with co-investigator MRR based at the 
orthopaedic ward at TAH. The investigators together made 28 pharmaceutical care 
plans from the cardiology ward and the orthopaedic ward, and then 2 care plans 
alone for the same two patients, one in each setting, in order to check if the data 
gathering process was performed in the same way. At the cardiology ward the 
investigators worked alongside the pharmacists MC and KW, and at the orthopaedic 
ward alongside pharmacist SMCK.  
 
A need for the development of a guideline for categorisation of care issues was 
identified when the investigators trained on categorising the care issues from the 30 
care plans. There was limited and relatively unspecific information available about the 
triangularised categorisation system used by previous students at the University of 
Strathclyde. The categorisation system the investigators were presented to is added 
as appendix 2. The investigators tried out this categorisation system in the beginning 
of the training period, but thought that it was difficult to comprehend and a decision to 
make a guideline was therefore made. 
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During this period the investigator also observed how pharmaceutical care was 
delivered in: 
• Medical receiving ward 
• Medical cardiology ward 
• Orthopaedic ward 
• Orthopaedic pre-op ward 
• Dispensary 
Based on observations from the medical cardiology ward drafts for process maps 
were made in Microsoft Visio ®. These maps were later altered based on feedback 
and verified to be valid for both the medical cardiology ward and the coronary care 
unit, by pharmacists MC and KW at the medical cardiology ward and GJ at the 




3.2 Ethical approval 
 
An application for ethical approval of the survey was sent to Ayrshire and Arran 
Health Board Ethics Committee. The committee considered the application together 
with the project protocol, the consent form and the patient information sheet, and 
approved the survey late in January 2008. 
 
The consent form and the patient information sheet were developed at the pharmacy 
department at the Ayr Hospital. The form was filed together with the patient’s medical 
notes, and the patient got to keep a copy of it together with the patient information 
sheet. A second copy of the consent form was filed together with the researchers 
notes. The patient information sheet contained a short presentation of the project and 
the investigators and informed the patients about the practical consequences of 
giving consent.  
 
The investigator personally asked all the newly admitted patients for consent to 
inclusion, and all patients were given verbal and written information about the project 
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by the investigator. The patients were given time to read the patient information sheet 
and urged to ask questions if they had any, before signing the consent form. If a 
patient didn’t want to be included in the survey, this was respected and the patient 
was thanked for taking the time talking with the investigator. 
 
 
3.3 Inclusion of patients 
 
During the inclusion period all patients that were admitted/transferred to the two 
wards and who received pharmaceutical care, were invited to participate in the 
survey. Patients with dementia or confusion documented in their medical notes or 
nurses notes were assessed as unable to give consent, and were therefore not asked 
to take part in the survey. In some cases the state of confusion improved during the 
hospital stay, and the patient were then asked to participate after the confusion had 
ceased. For one patient with dementia a relative signed the consent form, but 
otherwise this group of patients were excluded. 
 
 
3.4 Use of a care plan template for data gathering 
 
It was necessary for the investigator and the co-investigator to gather data in a 
common way, and a care plan template was therefore used. A standardised care plan 
template was custom made with elements from several templates developed at the 
University of Strathclyde. The investigator and the co-investigator developed the care 
plan template together, and both used it for the data gathering. 
 
The issue section of the care plan arranged for a common way of presenting the care 
issues among the investigators. In the care plans produced by the clinical pharmacist, 
the course of processes might be diffuse, several issues were often written together 
as one, and key information for categorising was sometimes missing. The investigator 
therefore invested a lot of time in rewriting all the care plans. This had to be done 
since a precise way of stating desired outcome, action and outcome was crucial when 
the issues later were subjects for content analysis. The template also contained a 
section for noting patient demographics, important for the subsequent comparison of 
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the two populations. The NICE guideline on harmful drinking was used to categorise 
alcohol consumption.  This guideline defines  “at-risk drinking” for women as 3 units of 
alcohol per day, and as 5 units per day for men35. 
 
The template used for the data gathering also served as a starting point for finding a 
template that could be used in an electronic prescribing system.  
 
An example of a free text care plan as it was written in the electronic prescribing 
system and data presented in the  care plan template used for the data gathering can 
be found in appendices 3 and 4 
 
 
3.5 Data gathering 
 
The initial aim was to include 120-150 patients from the medical cardiology ward at 
the Ayr Hospital during a recruitment period of maximum 8 weeks, starting in January 
2008. However, the approval from the ethical committee at the Ayr Hospital came 
through later than expected and so the recruitment started first in February. After the 
first week the investigator at the medical cardiology ward only had managed to 
include 3 out of 7 patients, and then the ward was closed for the next 8 days due to 
an outbreak of a gastroenteritis endemic caused by a norovirus. Due to these 
unexpected events, a decision was made to also include patients from the coronary 
care unit into the survey. In the result part the two wards will be analysed as if they 
were one ward. 
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Medical Cardiology Ward
Coronary Care UnitInclusion period: 04.02.08 - 17.03.08
Inclusion period: 11.02.08 - 17.03.08
Total number of patients 
included in to the survey: 71
Ward closed: 11.02.08 – 19.02.08
 
Figure 6 Number of patients included at the cardiology ward 
 
 
The included patients were followed prospectively from admission to the wards till 
discharge or transfer to another ward. Patients that were admitted to the wards during 
the inclusion period were identified through the daily bed state at the wards and the 
electronic prescribing system. The investigator kept track of how many patients that 
were admitted to the wards during the period, how many of them that were provided 
with pharmaceutical care, and the reasons why patients that had received 
pharmaceutical care were not included. The patients’ data were made anonym and 
coded, so that it was possible for the investigator to identify the patients when 
gathering clinical relevant information. 
 
Standardised care plans were made by the investigator for all of the 71 included 
patients during the prospective monitoring of the pharmaceutical provision. These 
care plans were made based on: 
• Pharmacist authors’ free text notes within the electronic prescribing system 
• Interviews with the pharmacist authors with reviews of the paper profiles when  
    necessary to verify the accuracy of the description of care delivered 
• The prescription data on the electronic prescribing system  
• Medical notes 
• Nurses’ notes 
• Discharge letter 
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With the above specified approach the investigator hoped to overcome gaps in the 
free text electronic records, and so document the care delivered in a precise manner. 
The action research approach was used during the survey, with the aim of giving the 
pharmacists feedback on their work at the same time as the investigator got feedback 
on their work. 
 
 
3.6 Development of a guideline for the categorisation system 
 
The investigators in Ayr cooperated on developing a guideline and making changes to 
the categorisation system with KJH and MBC, who both were doing a similar project 
at the Royal Infirmary in Glasgow. SH and CF at the University of Strathclyde gave 
guidance and inputs during this process. The guideline and the categorisation system 
was revised several times, and a lot of effort was invested in the development phase. 
During the development of the categorisation system it was continuously tested on 
samples of care issues, aiming that it would be possible to categorise all types if care 
issues in the system. The care issues were sampled from the 30 care plans made 
during the pilot phase at the Ayr Hospital and from care plans that the investigators in 
Glasgow used for their training. As the process continued, a set with practical 
examples for use of the categorisation system was made. 
 
 
3.6.1 Drug Therapy Problems 
 
It was specified in the guideline that only actual Drug Therapy Problems (DTP) would 
be categorised in this category. This decision was made since possible DTPs often 
could be assigned to more than one category, and the system needed to have 
categories that weren’t ambiguous. Especially for issues were the pharmacist were 
monitoring drug use and physiologic functions, a Drug Therapy Problem (DTP) 




3.6.2 Check and Change 
 
 
The intention behind using a categorisation system was to measure clinical 
pharmacy/pharmaceutical care in a quantitative manner, and it was therefore decided 
that not all of the checks the pharmacist performed would be categorised. Checks 
performed during the verification process of drug regimens were not defined as care 
issues, since those checks are a part of the pharmacists routine, and are performed 
for every patient that receives pharmaceutical care. For patients using a many of 
drugs, the number of checks performed in the verification process would be very high. 
A high number of verification checks could mean that all the other checks and 
changes performed would “drown” in all the information provided about the 
verification process, and this could potentially give a false picture of the 
pharmaceutical care provided.  
 
In appendix 2 a 5th check category, formulary adherence inquiry, were added to the 4 
original categories described by Strand et. al5. Using the same argumentation as for 
verification checks, it would not be interesting to categorise the number of times the 
pharmacist checks formulary adherence, and this category was therefore removed. 
 
A few of the sub categories for changes were altered, and extra categories were also 
added. It was decided to split the change category into 2 categories, since some 
changes could be further categorised into DTP categories while others could not be. 
A change that would fall outside the definition of DTPs would for instance be to 
increase the level of patient monitoring or to update the patients drug history. The 
new change categories was named: 
• “Changes in Drug Therapy”, could be further categorised in to DTP  
    sub categories 
• “Changes in Drug Therapy Processes”, could not be assigned to a DTP  






3.6.3 Quality Assurance Descriptors 
 
Since Quality Assurance Descriptors are used to the describe how pharmaceutical 
care is provided throughout the patients drug therapy, from start of therapy and until it 
is stopped, it was necessary to specify how the descriptors could be used in a 
hospital setting were  the pharmacist sees the patients in interim episodes.  
 
 
3.7 Verification of the categorisation system 
 
The categorisation system was subject for discussion and evaluation in a focus group 
held at the University of Strathclyde. The method  part on focus group is described 
later. 
 
100 care issues, 50 issues from each setting, were randomly chosen to be 
categorised by each co-investigator, and Cohen’s Kappa was used for measurement 
of inter rater agreement within the system. Inter rater agreement describes how the 
raters classify subjects into groups, compared to what is expected exclusively from 
chance. A poor Kappa can either mean that the system is ambiguous or that the 
raters them selves fail to use the system as intended. 
 
Before the raters performed the Cohen’s Kappa test all the hundred care issues were 
plotted into a matrix table similar to that used for finding Cohen’s Kappa. It was 
checked for if most of the categories had at least one care issue assigned to them, 
and since the care issues were distributed between nearly all the different categories, 





Table 15 Matrix for calculating Cohen’s Kappa 
 Rater 2 
 
 A B C D Total
A A.A A.B A.C A.D X1 
B B.A B.B B.C B.D X2 
C C.A C.B C.C C.D X3 
D D.A D.B D.C D.D X4 
Rater 1 
Total Z1 Z2 Z3 Z4 N 
 
Exact number of agreements observed: 
Atot = A.A + B.B + C.C + D.D 
 
Total eexpected frequencies by chance: 
 (X1+Z1/N) +( X2+Z2/N)+( X3+Z3/N)+( X4+Z4/N) 
 
Ac tot = [(X1+Z1/N) +( X2+Z2/N)+( X3+Z3/N)+( X4+Z4/N)] / N 
 
Maximum agreement is 1,00 
Max agreement by chance = 1,00 - Ac tot 
The observed agreement is = Atot - Ac tot 
 
Kappa: (= Atot - Ac tot) / (1,00 - Ac tot)  
 
 
Table 16 Interpretation of Kappa 
Value of Kappa Strength of agreement
< 0,20 Poor 
0,21 – 0,40 Fair 
0,41 – 0,60 Moderate 
0,61 – 0,80 Good 




3.8 Quantitative analysis of care provision in cardiology ward and 
orthopaedic ward 
 
The care issues and the patient demographics were plotted in to an Microsoft 
Access® database, and the care issues were then categorised according to the 
guideline. The investigators made queries in the data base, and each investigator 
subsequently processed the findings in Microsoft Excel ® and by using a GraphPad 
calculator36. 
 
The quantitative measures found for the cardiology ward and the orthopaedic ward 
were compared, and the distribution of care issues were evaluated statistically by chi 
quadrate- an t-tests. A zero hypothesis stating that there were no differences in the 
distribution of care issues between the two wards were set. 
 
 
3.9 Development of an care plan template 
 
The investigator and the co-investigator cooperated on arranging a group meeting for 
the pharmacists at the Ayr Hospital, where the development of an electronic care plan 
template was discussed. This meeting was held 21.04.08, one week prior to the focus 
group meeting held at the University of Strathclyde. The investigators presented 
some ideas for a template through a power point presentation and by handing out 
examples of care plans in use at different sites and settings. The meeting was 
structured as a workshop for discussion around ideas for an electronic care plan 
template, and it also encouraged the pharmacist to come with new inputs. Besides 
from the investigators and the clinical pharmacy manager, 4 of the clinical pharmacist 
attended the meeting. 
 
It was commented that some of the content in the proposed care plan template had 
resemblances with the Medicines Reconciliation Form in use at the present, and it 




After the first group meeting the investigators changed the template based on the 
feedback from the pharmaceutical team at the Ayr Hospital. The final template was 
presented at the focus group one week later, and the pharmacists from the Ayr 
Hospital were then asked to comment this draft as a verification of the template. 
 
 
3.10 Focus group 
 
 A focus group meeting was held at the University of Strathclyde 28.04.08. The focus 
group was held by the investigators at TAH together with KJH and MBC at the 
Glasgow Royal Infirmary. The main focus for the meeting was to evaluate the 
categorisation system and the guideline, but some time was also spent on getting 
feedback on the final care plan template. The meeting was structured around a 
power point presentation of the categorisation system and the results from the 
content analysis, and questions were asked for the different parts of the system and 
the following results. All four authors of the categorisation guideline shared on 
presenting and asking questions/being moderator. The focus group was tape 







4.1 Inter rater agreement 
 
 
The following tables shows the Cohen’s Kappa-values found for main categories and 
subcategories of check and changes and all subcategories for Quality Assurance 
Descriptors. Kappa-values are presented with a guiding interpretation of strength of 
agreement, but more importantly the values should also be evaluated by width of 
confidence intervals. 
 
Pr(e) denotes the proportion of agreement you can expect to find by chance alone, 
and Pr(o) the agreement observed. 
 
Table 17 Cohen’s Kappa tested for main categories of checks and changes 
  Investigator B 





Drug Therapy Total 




0 17 0 17 
Changes in 
Drug Therapy 2 2 24 28 
Total 57 19 24 100 
     
κ (CI) 0,93 (0,87-1,00)    
Strength of 
agreement Highly good    
Pr(o) 0,96    










Table 18 Cohen's Kappa tested for Checks, Changes in Drug Therapy Process and Changes in Drug Therapy 
Investigator B 
Checks Changes in Drug Therapy Process Changes in Drug Therapy  
Investigator A MED EFF SAFE COMP CHAR DH CONT MON INF SEL DOSE FORM INT DUR STOP EDU Total 
MED 11 1   1                         13 
EFF 4 12                             16 
SAFE     24                           24 
Checks 
COMP       2                         2 
CHAR         1                       1 
DH           15                     15 
CONT             1                   1 





INF                 0               0 
SEL 1         1       8             10 
DOSE     1     1         4           6 
FORM                       0         0 




DUR                           0     0 
STOP                   1         9   10   
EDU                               1 1 
Total        16     13 25 3 1 17 1 0 0 9 4 0 1 0 9 1 100 
                   
K (CI) 0,87 (0,46-1,28)                    
Strength of  
agreement: Highly Good                   
Pr(o) 0,89                   
Pr(e) 0,85                    
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Table 19 Cohen’s Kappa tested for Quality Assurance Descriptors: Time Perspective 
Investigator B Investigator A 
Verification Monitoring Confirmation Total
Verification 44 1 0 45 
Monitoring 7 42 4 53 
Confirmation 0 1 1 2 
Total 51 44 5 100
     
κ (CI) 0,76 (0,64-0,88)    
Strength of 
agreement Good    
Pr(o) 0,87    
Pr(e) 0,46    
 
 
Table 20 Cohen’s Kappa tested for Quality assurance descriptors: Degree of change 
Investigator B Investigator A 
Adjustment Modification Review 
Total
Adjustment 16 2 0 18 
Modification 3 2 0 5 
Review 0 0 1 1 
Total 19 4 1 24 
     
κ (CI) 0,44 (0,18-0,69)    
Strength of 
agreement Good    
Pr(o) 0,79    









4.1.2 Results from the Focus group regarding the categorisation system  
 
The following table lists the participants in the focus group meeting held at the 
University of Strathclyde 28.04.08. 
 
Table 21 Participants of the Focus Group 
Title Work place Initials 
Professor of pharmaceutical care University of Strathclyde SH 
Clinical pharmacist Glasgow Royal Infirmary CF^ 
Clinical pharmacist Glasgow Royal Infirmary LS 
Investigator Glasgow Royal Infirmary KJH 
Investigator Glasgow Royal Infirmary MBC 
Clinical pharmacy manager/ 
Clinical pharmacist 
 
The Ayr Hospital GJ* 
Clinical pharmacist The Ayr Hospital KW 
Investigator The Ayr Hospital ROH 
Investigator The Ayr Hospital MRR 
 
^Said he had not read the whole guideline prior to the focus group meeting. 
* Came in late and only attended half the focus group meeting. 
 
Recommendations for improving the categorisation system 
 
The participants in the focus group had several recommendations for an improvement 
of the categorisation system. One of the main things that were emphasised in the 
focus group meeting were the need for a proper language for describing 
pharmaceutical care, and that some changes will have to be made in the 
categorisation system in order to meet this need. It was also said there is a need to 
train pharmacists in care planning, including the use of categories. 
 
It was pointed out that the category name Change in Drug Therapy Process was 
misleading, since the pharmacists considered their contributions in the subcategories 
as a part of the drug therapy process it self. It was therefore suggested that this 
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category should be renamed Contribution to Drug Therapy Process, and there was 
general agreement for this proposal. It was remarked that the overall class still will be 
Change, because if not you would be saying that these contributions are neither 
checks nor changes. 
 
None of the investigators had categorised any issues into the Duration subcategory, 
and they had all used the Stop and Start categories in stead of this category. The 
focus group participants were therefore asked for their opinion regarding the need for 
this subcategory. It was stated that the pharmacists usually talk about duration of 
therapy, and it was expressed that it is desirable to categorise changes made to the 
duration of therapy. It was therefore suggested to alter the name of this category, so 
that it would be easier to categorise duration issues as such, and the proposed new 
name was Change in the length of course. 
 
It was raised concerns about the category Unclassified DTP, since this is an addition 
to the original seven Drug Therapy Problem categories, a system which shouldn’t be 
altered without talking to the authors first. It was also suggested to give this category 
a more specific name, so it becomes easier to see that this category is only for non-
formulary drug changes, and not for any other issues that are hard to categorise. The 
focus group participants were asked if they thought this category had a place in the 
categorisation system since it doesn’t describe clinical care issues. The feedback 
emphasised that switching to formulary drugs is something that the pharmacists 
spend time on doing, and that you would loose a part of the pharmacists actions if 
you didn’t have a category for them. It was also asked rhetorically to what extent you 
want to separate out impact on cost and impact on patient’s symptoms. 
 
In addition to categorising care issues as described in the guideline, the number of 
care issues where an interaction was mentioned, and the number of 
recommendations made to the prescriber were counted. The focus group participants 
were asked to comment if an interaction category should be a part of the system, and 
there was agreement for that there is no need for such a category. It was pointed out 
that checking for interactions is just one of the actions the pharmacist undertakes in 
order to identify care issues, and that the information you really are interested in are 
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the outcomes. The pharmacists also stated that they won’t write it down when they 
check for interactions.  
 
The focus group participants also asked to comment if it would be useful to implement 
recording of recommendations made to the prescriber in the categorisation system. 
The participants had trouble understanding and interpreting the data the way they 
were presented here, and the final conclusion to this question was therefore that 
measuring recommendations could be useful, but that usefulness depends on what 
you are using the data for.  
 
The general feedback on Quality Assurance Descriptor categories as they were 
described in the guideline, were that they were hard to comprehend. It was suggested 
that the Time Perspective categories both should be redescribed and renamed. It was 
suggested to rename them Change in Design Stage, Change in Delivery Stage and 
Change in Evaluation Stage, since the present names are used for other resembling 
processes and this gets confusing. It was expressed that an agreed language is very 
important here, and that it is a problem that this is lacking today. For the Degree of 
Change categories it was stated that the difference between categories were hard to 
comprehend, and it was also suggested to separate modifications made in the design 
stage as opposed to the evaluation phase. 
 
In the table on the next page the recommendations made for improving the 















Table 22 Summary of recommendations made about the categorisation system 
• Rename the category Change in Drug Therapy Process to Contribution to 
Drug Therapy  
• Make a clearer division between starting/stopping a drug by and altering the 
duration of therapy by renaming the Duration subcategory to Change of the 
length of Course 
• Keep a subcategory for categorising non-formulary issues, but move the it 
out of Drug Therapy Problems 
• Useful to categorise the outcomes seen from checking for interactions, but 
no purpose in recording the number of interactions found per se 
• Recording the number of recommendations made can be useful 
• The subcategories in Quality Assurance Descriptors, Time Perspective 
should be renamed as Change in Design Stage, Change in delivery Stage 
and Change in Evaluation Stage. These subcategories should also be re-
described 
• Finding a way of separating the modifications that were documented in the 
design stage as opposed to in the evaluation stage 
 
 
Strengths and weaknesses with the categorisation system 
 
Some of the comments from the focus group participants regarding the strengths and 
weaknesses of the categorisation system is gathered in the table 29. 
 
Some of the comments from the focus group participants explaining the results seen 
in the quantitative analysis of care issues is gathered in table 30.
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Question/ Topic Comments 
What is your first impression 
of the guideline? 
Is it possible to use the 
system after reading the 
guideline? 
- I think the concept of time perspective is a little bit unfocused (SH) 
- I find it a bit complex, reading it (LS) 
- I think checks and changes, that’s fine. But if you are actually modifying or adjusting things, or 
confirming and verifying things, that means two different things? You would need to know what 
language to use in this context (LS) 
- I agree with that. Reading it through, initially I got the whole check and change thing. But then, I 
had to read it three times to understand the range of it (KW) 
Are any categories you 
would like to see or that are 
missing? 
- I think you got the basis of a degree of describing a lot of the activity ofpharmacist contributions 
to care (…)There’s a quite a difference between Ayr and Glasgow (CF) 
- It’s useful for a pharmacist to see as well (…)You need to start to think is that because of my 
patient case load, or is it because that’s something I don’t do often enough? (LS) 
Which potential uses you 
can think of for this system? 
Can you mention anything 
positive and negative sides 
about the system? 
- Pharmacist can benchmark their practice and see what they need to be working on. (..) It 
makes you thinking: it makes you thinking about process (LS) 
- The negative is that’s quit complex (LS, KW, GJ) 
- I think that it could potentially lead to inter-rater problems. I know you guys have been working 
quit closely, but if you were isolated from each other and you came back together: would you 
probable be the same way? (LS) 
- The more intuitive you can make it, the better. (LS, agreement) 
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Table 24 Results from focus group regarding outcomes from categorisation of care issues 
Question/ Topic Comments 
Distribution of care issues in the sub 
categories of checks varies, can this be 
explained? Is it expected? 
- The expected compliance is quite high in care of the elderly, it is not really that 
surprising in all (LS) 
Distribution of care issues in the sub 
categories of Change in Drug Therapy 
Processes varies, can this be explained? 
Is it expected? 
- I think the clinical, sort of shared record, drug history, ist probably so high on the 
Ayr side because the medical staff very much leaves that up the pharmacist, 
whether that’s right or wrong, to sort out the drug history and  to transcribe 
everything on admission so that probably makes the number pretty much as 
predicted (KW) 
Electronic prescribing and a high number 
of stopped drugs 
- That is due to a problem with the electronic prescribing system, because the 
doctor can easily suspend the drug on the electronic system, so that we think 
the drug should probably be stopped, but they often just suspend it and that 
generates some extra care issues (….) Basically, another problem with the 
electronic prescribing system. So that’s why its so high. And if its not stopped it 
will appear in the discharge letter, so there is a risk attached to it (KW) 
- So, electronic prescribing brings in problems of it’s own. That’s an interesting 
finding. (CF) 
- Actually, we need to go back to our service to make sure (…) It’s a new sort of 
error, to suspend drugs (GJ) 
Quality Assurance Descriptors, Time 
perspective 
- You probably have more confirmation checks than you are actually documenting 
(CF) 
Quality Assurance Descriptors, Degree of 
Change 
- I’m surprised there were not many reviews, generally. (SH) 
- Maybe the patients are,  I just think that cardiology has quiet short stay. There 
are also sort of simple treatments, treatments as per, after a set of guidelines. 
(KW) 
- I would thought that prompting a review is much more likely if you are attending 
a ward round (SH) 
Documenting care issues - I wouldn’t routinely write down checking for everything. (LS) 
- I wouldn’t write down a drug interaction (CF) 
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Medical Cardiology Ward Coronary Care Unit
Inclusion period: 04.02.08 - 17.03.08 Inclusion period: 11.02.08 - 17.03.08
Total number of patients admitted to the ward: 125 Total number of patients admitted to the ward: 45
Total number of patients seen by pharmacist: 80 Total number of patients seen by pharmacist: 42
Number of participants: 32
Number of participants included at 
the ward: 30
Number of participants included at 
medical cardiology ward: 2
Number of participants: 49
Number of participants included at 
the ward: 41
Number of participants included at 
CCU: 8
Number of participants with a 
care plan already started: 43
Number of participants with a 
care plan already started: 2
Patients that was seen by 
pharmacist but not included: 31
Declined: 11
Unable: 14
Missed by investigator*: 6
Patients that was seen by 
pharmacist but not included: 10
Declined: 3
Unable: 7
Missed by investigator: 0
* 4 patients were missed 
because the ward was 
closed, and 2 patients were 
missed because they were 
discharged before the 
investigator had a chance to 
get consent from them
Number of patients not seen by pharmacist: 45 Number of patients not seen by pharmacist: 3
Total number of patients 
included in to the survey: 71
 
Figure 7 Patients included from the cardiology ward 
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71 patients were included from the cardiology ward while 90 patients were 
included from the orthopaedic ward, and 63% of the patients included from the 
cardiology ward were male compared to 40 % at the orthopaedic ward. The 
orthopaedic ward is bigger than the cardiology ward, with 36 beds compared to 
30 beds on the latter ward. 7.0% of the admissions to the cardiology ward were 
panned. Table 16 shows the most common presenting complaints for the patients 
included from the cardiology ward. 
 
Table 25 Most common presenting complaints at the cardiology ward 
 Patients (%) 
CP 11 (15,5) 





STEMI 7 (9,9) 
ACS 7 (9,9) 
 
 
Patients with STEMI and ACS usually also had CP, but these cases are not 
counted in the category CP. The CP category includes only the cases where CP 
was presented without ACS, NSTEMI or STEMI suspected. 
Table 26 Alcohol consumption, smoking status and alcohol consumption 
 Alcohol consumption 
 
















 Smoking status 
 



























*BMI was not available from the orthopaedic ward 
^n=56, numbers were not available for all 71 included patients 
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Number of drugs on admission and drug history (DH) sources are summarised in 
the table below. The to biggest contributions to the category Other are electronic 
care summaries and repeat lists. 
 
Table 27 Sources for drug history 
 Cardiology Orthopaedic 
Total number of drugs  
on admission 
398 468 
Mean  (CI) 5.6 (4.4-6.8) 5.2 (4.4-5.9) 
Median (IQR) 4.0 (1.5-9.0) 5.0 (2.3-7.0) 
Range 0-23 0-14 
p = 0.53   
Frequency distribution  
(% of total number of patients)   
Number of patients n=71 n=90 
Number of sources used per patient    
0  0 (0.0) 9 (10.0) 
                                         1 26 (36.6) 23 (25.6) 
2  40 (56.3) 52 (57.8) 
                                            3 5 (7.0) 5 (5.56) 




(% of total DH sources) 
Total number of sources used to 





Patient 39 (31.7) 56 (38.4) 
Patient’s own drugs (PODs) 14 (11.4) 40 (27.4) 
Patient’s relatives 5 (4.0) 2 (1.4) 
General Practitioner Surgery 16 (13.0) 19 (13.0) 
General Practitioner letter 8 (6.5) 8 (5.5) 
Community Pharmacy 5 (4.0) 2 (1.4) 
Previous discharge letter 12 (9.8) 4 (2.7) 
Notes 7 (5.7) 0 (0.0) 




A comparison of patient characteristics and pharmaceutical care activity is 
presented in the table below. The table presents the results per patient in mean 
values with confidence intervals (CI), median values with inter quartile range 
(IQR) and range of parameter. The p-value denotes if there are any significant 
deifferences between the two wards. 
 
Table 28 Comparison of Patient Characteristics and Pharmaceutical care activity 




















































































































* Total number of care issues = Total number of categorised care issues. 
^ Care issues with no outcome = Total number of care issues not categorised. 
 
α=0.05 have been used for 95% CI. 
p>0.05 means that the null hypothesis remains, and that there is no 
demonstrable difference between the to populations, while a p<0.05 means that 
there is a 95% likelihood of a real difference between the two populations based 
on the comparison of the two samples. The closer the p-value approaches zero 
respectively, the greater the likelihood of a real difference. 
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The proportion of care issues distributed in subcategories for check and changes 
are given in the table below. The proportions are given as percents with 
confidence intervals. A chi square test was performed to test statistical 
significance of distribution, and the p-values found are presented in the table. 
 
Table 29 Comparison of distribution of care issues in subcategories of checks and 
changes 
  Cardiology Orthopaedic   
 n % n % p-value 
    (95 % CI)   (95 % CI) (chi square) 
Checks      
Total 
 
267  99   
27 10.1 59 59.6 < 0.0001 Medication need inquiry 
 
 (7.0, 14.4)   (49.7, 68.7)  
83 31.1 15 15.1 0.0021 Effectiveness inquiry 
 (25.8, 36.9)   (9.3, 23.6)  
142 53.2 23 23.2 < 0.0001 Safety inquiry 
 (47.2, 59.1)   (16.0, 32.5)  
15 5.6 2 2.0  0.17 Compliance inquiry 
 
 (3.4, 9.1)  (0.1, 7.5)  
Changes in  
Drug Therapy Process      
Total 
 
69  77   
Clinical (shared) record of 
patient characteristics 
11 15.9        
(9.0, 26.5) 
0 0.0         
(0.0, 5.7) 
< 0.001 
Clinical (shared) record of  
drug history 
37 53.6      
(42.0, 64.9) 
63 81.8      
(71.6, 89.0) 
<0.001 
Continuity of information/ 
care between  
clinical settings 
11 15.9        
(9.0, 26.5) 
5 6.5         
(2.5, 14.7) 
0.11 
2 2.9 3 3.9  1.0 Level of patient monitoring 
 
 
(0.2, 10.6)  (0.9, 11.3)  
Health care team member(s)  
information/education 
8 11.6        
(5.7, 21.5) 




Table 35 (cont.) Comparison of distribution of care issues in subcategories of 
checks and changes 









(95 % CI) 
p-value 
(chi square) 
Drug selection      (starting 
new or changing drug) 
6 14.3        
(6.3, 28.2) 
35 37.2      
(28.1, 47.3) 
0.0082 
Dose 6 14.3 6 6.4 0.19 
  
 
(6.3, 28.2)  (2.7, 13.5)  
0 0.0 13 13.8 0.0095 Route/ 
dose-form  
 
(0.0, 10.0)  (8.1, 22.4)  
0 0.0 5 5.3 0.32 Dose  
interval/timing  
 
(0.0, 10.0)  (2.0, 12.2)  
Duration 0 0.0 0 0.0 1.0 
  
 
(0.0, 10.0)  (0.0, 4.7)  
Stop drug  
temporarily/ 
permanently 
23 54.7      
(40.0, 68.8) 
30 31.9      
(23.3, 41.9) 
0.014 
Patient or carer level of 
education 
(Understanding/compliance) 
7 16.7        
(8.0, 30.9) 







The proportions of care issues distributed within the Drug Therapy Problem 
subcategories are presented in table 29 
 
Table 30 Distribution of Drug Therapy Problems  
within the cardiology ward and the Orthopaedic ward 
 Cardiology Ortopaedic
 N (%) N (%) 
Unnecessary drug therapy 16 (38.1) 27 (28.7) 
Need for additional drug therapy 3 (7.1) 28(29.8) 
Ineffective drug 1 (2.4) 9 (9.6) 
Dosage too low 5 (11.9) 7 (7.4) 
Adverse Drug Reaction 5 (11.9) 11 (11.7) 
Dosage too high 4 (9.5) 4 (4.3) 
Inappropriate compliance 8 (19.0) 7 (7.4) 




The distribution of care issues into Quality Assurance Descriptors were tested the 
same way as in check and changes, and the results are presented in table 37. 
 
Table 31 Categorisation of all issues into QA Descriptors  
             Cardiology          Orthopaedic   
 n %         n % p value 
    (95% CI)   (95% CI) (chi square) 
Checks 
Verification 68 25.5      
(20.6, 31.0)
27 30.7      
(22.0, 41.0)
0.79 
Monitoring 199 74.5      
(69.0, 79.4)
50 56.8      
(46.4, 66.7)
< 0.0001 
Confirmation 0 0.0         
(0.0, 1.7) 
22 25.0      
(17.1, 35.0)
< 0.0001 
Total 267  88   
Changes in Drug Therapy Process 
Verification 49 71.0      
(59.4, 80.4)
69 89.6      
(80.6, 94.9)
0.0058 
Monitoring 20 29.0       
(19.6, 40.6)
8 10.4        
(5.1, 19.4) 
0.0058 
Confirmation 0 0.0         
(0.0, 6.3) 
0 0.0         
(0.0, 5.7) 
< 0.0001 
Total 69  77   
Changes in Drug Therapy 
Verification 22 52.4      
(37.7, 66.6)
55 58.5      
(48.4, 68.0)
0.58 
Monitoring 15 35.7      
(22.9, 50.9)
30 31.9      
(23.3, 41.9)
0.70 
Confirmation 5 11.9      
(47.3, 25.5)
9 9.6         
(4.9, 17.4) 
0.76 
Total 42  94   
Adjustment 31 73.8      
(58.8, 84.8)
81 86, 2     
(77.6, 91.9)
0.092 
Modification 9 21.4      
(11.5, 36.2)
13 13.8        
(8.1, 22.4) 
0.32 
Review 2 4.8         
(0.5, 16.7) 
0 0.0         
(0.0, 4.7) 
0.094 
Total 42  94   
 
 
In addition to categorising the care issues identified for the patients included into 
the survey, it was recorded every time the pharmacist made a recommendation to 
the prescriber. A recommendation lead to a change in Drug Therapy  or Drug 
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Therapy  Process when the prescriber acted upon it, and if it wasn’t acted upon 
the care issue remained a check. 
 
 












Recommendations made for which the 
care issue remained a check 
Count










Recommendations which lead to a 
change in Drug Therapy Process 
Count










Recommendations which lead to a 
change in Drug Therapy 
Count













4.3 Care plan template 
 
The following figure shows the suggestion for a care plan template as it was 
presented in the focus group meeting 28.04.08: 
    
 PHARMACEUTICAL CARE PLAN 
Review  
[review date]  
    
 
 
[Patient identification]  
    
 
Presenting Complaints  
[free text box] 
[sign/ 
date]  
    
 
Past medical history  
[free text box] 
[sign/ 
date]  
    
 
Relevant Drug History  
[free text box] 
[sign/ 
date]  










specify if not oral 
Dose Frequency Sign 
 
 











specify if not oral 
Dose Frequency Sign 
 
 
    [sign/ 
date]  
       












  [sign/ 
date]  
     
     







 GP surgery  PODs [sign/ 
date]  
  GP letter  Nursing home   
  Discharge letter  Medical notes   
  Patient  Electronic Care Summary System  
  Patient’s family [freetext box]   
  Community pharmacy [freetext box]   
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  Date    Date Date Date Date Date  
 Weight    BP      
 Height    HR      
 BMI          
 
 
Laboratory Results  
 
 Date Date Date Date Date Date 
 
 Test Range Units        
 K 3.5-5.0 mmol/l        
 Na 135-145 mmol/l        
           
 Free text  
 [freetext box]         
          
          
 
 
Pharmaceutical Care Issues  
 
  Active 




































 Discharge  
        
 
  Active 





































 Discharge  
         




4.2.1 Structure and functions for the template 
 
Free text boxes was chosen for “Presenting Complaints”, “Past Medical History” 
and “Relevant Drug History”, as it was regarded that no more structure is 
necessary in these sections. 
 
The section “Admission Medicines” have structures resembling those in the 
“Medicines Reconciliation Form”, except for the omission of columns for making 
comments, and noting alterations that needs to be done. It is desired to have an 
inter connection between the prescribing section in POE and this part, so that 
when the pharmacist verifies the medicines on admission, and marks them as 
such in POE, these same drugs will appear in the care plan. 
 
The pharmacists wanted to have a box for allergy status even though there is 
one already in POE, since they always check allergies for patient on admission 
and want to document this. 
 
 It is desired that only the ticked boxes for “drug history” sources should appear 
in the care plan. 
 
It should be possible to make an intra link between the “patient demographics” 
part in POE to the “Investigations” section in the care plan template, so that 
weight and height measures can pop up in the care plan as well. With an 
electronic template it will also be possible to add a function that calculates BMI or 
body surface area from both metric measures and stones/feet. Other calculations 
that it would be useful to have functions for is eGFR, digoxin level, through 
concentrations and etc.  
A similar inter link could be made between the electronic lab result reporting 
system (Skye by JAC Computers) and the care plan template. Values chosen to 
be relevant by the pharmacist could then pop up in the care plan once they are 
plotted into the lab result reporting system. It is also desired that all values out of 
range automatically are presented to the pharmacist in this way. 
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The care issue section where the template intentionally splits the issues in to 
desired outcomes, actions and outcome, were pointed out to be the most 
important part in a new care plan by the pharmacists at TAH. This section of the 
template also have many potentials for further development; an intra link could 
ensure that drugs the pharmacist withhold verification for, automatically are 
presented as care issues in the care plan. The pharmacist can then later go back 
in the care plan and write out the care issue, state why the verification was 
withheld and how the care issue further is to be handled. 
 
Every care issue should be assigned a review date, and the issues could 
subsequently easily be prioritised by these dates. Tick boxes for active or 
inactive issues can similarly be sorted to the top and the bottom of the care plan 
respectively. The first coming review date would automatically be chosen as the 
whole care plan’s review date and appear at the top of the care plan. If the 
patient is not seen on this specific date, then the review date automatically will be 
updated until the patient is seen again or discharged. It might also be of interest 
to have ward summaries made, that list inpatients and their review dates. This 
overview will also include patients with no care plan started, indicating that they 
have not been seen by a pharmacist yet. 
 
It is desirable to have the possibility for writing the number of days till review in 
the “review” box, and then have this date converted to the specific date for the 
review. Issues relevant for discharge can be marked by ticking the discharge 
box, and these issues will be prioritised between the other active issues and the 
inactive ones. 
 
The Medicine Reconciliation Form in use at present have some sections that 
intentionally are omitted in addition to the columns for planned changes to the 
patients drug regimen, and these are sections that notes the need for a 
compliance aid, information about their community pharmacy and etc. The 
intention is that this information should be written in the care issue section of the 
template, and thereby also treated as care issues. 
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An example of how a free text care plan can be rewritten in the template is 
showed in appendices 7 and 8. 
 
 
4.2.2 Feedback from the Focus group on the final care plan template 
 
There was just a little time to discuss the care plan template at the end of the 
focus group, and most of this time was spent on presenting the template to the 
group participants. The key comments are listed in the table below. 
 
 
Table 33 Key comments from focus group on the care plan template 
- Ideally don’t  want duplication of information, want implementation 
- Information presented in the Medicines Reconciliation Form should make  
- the basis for a care plan 
- The care plan template that was presented captured the needs  
- Connecting the categorisation system to the care plan template would  
- make the date base complex 
- Unfortunately there is little interest from the software supplier’s side to  
- make a care plan template, since suppliers primary user group in  







5.1 The categorisation system 
 
5.1.1 Utility and validity of the categorisation system 
 
The utility of the categorisation system affected the inter-raters ability to 
categorise the care issues into the same categories. The strength of agreement 
for the main categories of check and changes were highly good, with both the 
confidence interval and the Kappa value being within an interval for 0.81-1.0. The 
strength of agreement for categorisation into all the subcategories for check and 
changes also had a highly good strength of agreement, but the confidence 
interval in this test was very wide and had a lower limit within moderate strength 
of agreement. The observed proportion agreement was just a little higher than 
what you could expect from chance alone. The raters showed the highest 
inconsistency between the medication need and the effectiveness subcategories 
for check. 
 
Inter-rater agreement were not performed for DTPs, since this is a well known 
categorisation system. The focus for the evaluation of the validity was therefore 
the altered check and change system and the new system with Quality 
Assurance Descriptors. Since Cohen’s Kappa both tests the validity of systems 
but also the raters understanding of it, a poor inter-rater agreement can be seen 
when well known systems are used. The raters have assumed that their 
agreement would have been good or highly good. 
 
The tested Cohen’s Kappa for Quality Assurance Descriptors, Time Perspective  
gave a good strength of agreement, with the lower limit of the confidence interval 
also being within the interval for “good”. 
 
Quality Assurance Descriptors, Degree of Change had a moderate strength of 
agreement, with a wide confidence interval that had its lower limit within the “poor 
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strength of agreement” interval. The raters showed inconsistency in categorising 
issues to adjustment and modification categories. 
 
The inter raters had worked close together during the development of the 
guideline and with the data gathering, and this may have contributed to a better 
inter-rater agreement than what otherwise would have been found. The fact that 
the raters had developed the guideline that was used them selves, may also 
have contributed to a better agreement. The inter-rater agreement found here 
can be used to evaluate the data found by the quantitative analysis of care 
issues, but not necessarily for a measuring how good the categorisation system 
per se would be for other raters than the investigators in this project. 
 
The type of issues that most often were categorised inconsistently are presented 
in section 5.1.2 
 
5.1.2 Type of care issues categorised inconsistently 
 
Some trends were recognised regarding the type of care issues that were 
categorised differently between the raters.  
 
The most abundant type of categorisation mismatches were the following: 
• There was found 5 checks that had been categorised as both medication 
need and effectiveness. Example: 
o The desired outcome was to ensure that a treatment with K supplements 
were effective. The pharmacist monitored K levels and subsequently 
advised the doctor to stop these supplements, an advice which didn’t 
lead to any changes. The check here was categorised as a medication 
need inquiry by one rater and as an effectiveness inquiry by the other 
rater.  
o Either category can be chosen for this issue, since the pharmacist 
actually checks for both medication need and effectiveness. The 
medication need will however depend on the effect the patient  
experiences, and the guideline should therefore state that the 
effectiveness category is the preferred one. 
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• There was found 8 changes in Quality Assurance Descriptors, time 
perspective that had been categorised as verification and  monitoring. 
Example: 
o A care issue describes that the pharmacist monitors if antibiotics should 
be started, and this decision depends on test answers from the 
laboratory. The results from the test shows that there is no need to start 
antibiotic treatment. This issue was categorised as a verification by one 
rater and as a monitoring by the other, while both raters recognised a 
check for medication need. 
o The definition of verification in the guideline says that a verification is 
done when the pharmacist first see the patient, and refers to a time 
aspect for when a check is performed. The word verification can be 
misleading in this situation, since it is easy to think that it has been 
verified that there is no need for antibiotic treatment. This is not a 
verification since the patient has been seen by the pharmacist for this 
care issues once before when the results from the laboratory comes. 
o One of the raters recognised that the pharmacist was monitoring the 
need for medication, but once the results from the laboratory was 
reported and a decision regarding the need for drug therapy was made, 
the need for drug therapy was no longer monitored for, and the care 
issue was no longer be in the monitoring phase. 
o The definition of confirmation as it is in the guideline today, specifies that 
confirmations are made when drug therapy is started and then later 
reviewed, so this category doesn’t either really fit this issue, since the 
drug therapy never was initiated. 
o In this case the pharmacist monitors for the initiation of a drug, but the 
issue remains a check since the outcome was that there is no need for 
drug therapy. There is no category for issues such as these in the 




• There was found 5 changes in Quality Assurance Descriptors, time 
perspective that had been categorised as monitoring and confirmation. 
Example: 
o The pharmacist monitors for duration of Flucloxacillin and think that the  
planned stop date stop date makes the duration of therapy too long. The 
pharmacist asks the doctor if the long duration is intentional, and receives 
an ambiguous answer. The pharmacist therefore assumes that the stop 
date is intentional. 
o One rater thought that an assumption can’t be regarded as an confirmation 
and categorised the issue as an monitoring, while the other categorised it 
as a confirmation. 
Example: 
o The pharmacist monitors use of laxatives and checks discharge prescription 
of Senna with administration details. The patient had not used Senna and 
the drug was therefore not supplied for discharge. One rater categorized 
this as a confirmation while the other as a monitoring. 
o The word monitoring in the care issue text probably leaded the rater to give 
this care issue the time aspect monitoring. 
 
• There was found 5 changes in Quality Assurance Descriptors, Degree of 
Change that had been categorised as adjustment and modification. Example:  
o In a care issue where the dose interval was changed from tid to PRN for 
diclofenac due to poor renal function, the outcome was categorised as an 
adjustment and a modification.  
o The the two terms are vague and subjective, and that is probably why the 
raters have used both categories for this an other issues. An adjustment is 
a change within a treatment plan while a modification is made outside the 
treatment plan and is an unexpected event. The problem with Degrees of 
Change is that a detailed treatment plan often don’t exist for many drugs, 
and therefore it is hard to categorise issues into adjustments and 
modifications.  The raters were students with little clinical experience, and 
they therefore had trouble recognising a treatment plan based on 
information available from the patient’s care plan. It was stated in the focus 
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group by an experienced clinical pharmacist that the two terms seemed 
similar to him also, and there were general agreement among the 
participants that degrees of changes was difficult to comprehend without 
reading the guideline several times first. 
 
 
Other typical differences in categorising between the raters: 
• Some issues that were categorised into two different subcategories 
necessarily also had to be categorised differently in the following 
category/categories. An example of this is a care issue where Lactulose was 
suspended and the pharmacist prompted that it was stopped in stead. One of 
the raters categorised the change as a confirmation and an modification, 
while the second rater categorised it as a monitoring and an adjustment. 
Referring to table 9 in the guideline one can see that a care issue categorised 
as a monitoring subsequently can’t be categorised as  modification. A 
confirmation can not be categorised as an adjustment. What have happened 
in this care issue was the following: 
o One rater regarded the change to be an adjustment and therefore 
chose the monitoring category, even though this category  don’t fit 
o The other rater recognised that the change was made in the 
confirmation time aspect, and therefore also had to chose the 
modification category 
It would probably be more appropriate to categorise this issue as an 
confirmation and an adjustment, and the guideline should therefore be 
changed so that this become possible. 
 
• The patient is on several analgesic drugs, and there is a duplication of regular 
dihydrocodeine, regular paracetamol and Co-codamol PRN. On the 
pharmacists initiative this is changed to regular dihydrocodeine and 
paracetamol PRN. This care issue was categorised in the DTP sub categories 
unnecessary drug therapy and dose too high. Co-Codamol contains 
paracetamol and codeine, and so multiple drugs are used to treat the same 
condition, which goes under the unnecessary drug therapy class. To drugs 
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containing paracetamol is however also used, and the category dose too high 
was therefore used. A guideline will never be able to give specific information 
on how every possible care issues should be categorised, but the goal is to 
find a categorisation system that is so intuitive as possible as this will 
increase the inter-rater reliability. 
o If the two raters did not agree on whether a check or a change was 
performed, the care issue would also subsequently be categorised into 
different issue Co-Codamol was changed to Paracetamol on the 
pharmacist’s request, and the raters categorised this change as a stop and 
a drug selection. While the actual outcome was that Co-Codamol was 
changed to Paracetamol, the outcome stated in the database was that co-
codamol was stopped. Since one rater knew what the actual outcome was 
and the other did not, this lead the second rater to categorise the issue 
into the wrong category. Mistakes like this one could have been avoided if 
all issues were stated precisely.  
 
 
5.2 Ward descriptions and quantitative comparison of 
pharmaceutical care provided at two hospital wards 
 
There were no statistically significant differences between the two patient 
populations with regards to age, number of diagnoses on admission and number 
of drugs on admission. More men were admitted to  the cardiology ward than the 
orthopaedic ward, and this can be partly explained by the correlation between 
men and cardiovascular diseases, and between women and osteoporosis. 









5.2.1 Drug History 
 
Sources used for confirming drug history was documented in the care plans for 
all patients at the cardiology ward, while this information was missing for 10% of 
the patients at the orthopaedic ward. 
 
On both wards the most commonly used sources for drug history were the 
patient, PODs (patient’s own drugs) and the GP surgery. The patient their selves 
was asked about drug history in 54.9% (39/71) of the cases on the cardiology 
ward. This number was expected to be higher, since all except one patient 
included in the survey were able to give consent for this their selves. The 
patient’s own explanation of how the drugs actually are used, if all the prescribed 
drugs are used and if any additional OTCs or herbals are used, is of great value 
whenthe validation of the drug history, and the patient should therefore ideally 
always be interviewed about drug history. PODs were more often used for 
confirmation of drug history at the orthopaedic ward, and this was as expected 
since PODs are used by inpatients at the orthopaedic ward and not at the 
cardiology ward. GP letters were not commonly used in either ward, and this  
may be explained by the fact that GP letters are regarded as unreliable in 
addition to the fact that many of the admissions weren’t planned and a GP letter 
therefore never was sent. 
 
5.2.2 Quantitative comparison of the distribution of care issues 
 
The quantitative comparison of the wards are based on the care issues the 
pharmacists have documented in the care plans, and a bias to the interpretation 
of results would be if certain types of issues don’t get documented. 
 
The pharmacists at the cardiology ward identified and documented more care 
issues than the pharmacists at the orthopaedic ward, with a mean value of 5.3 
care issues found per patient compared to 3.0. There was no difference between 
the two wards in the number of care issues that were started but had no 
documented outcome, and a contributing factor to this may be that care issues 
that were followed up at the dispensary, were categorised for the cardiology 
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ward. The higher number of care issues per patient at the cardiology ward can 
be explained by a higher number of documented Checks. The pharmacist 
coverage were lower than it usually is on both wards during the survey period, 





The distribution within the Check categories differed between the two wards, with 
differences seen in the distribution of Medication need, Effectiveness and Safety 
inquiries. 
 
A higher percentage of Effectiveness and Safety checks and a lower percentage 
of Medication need checks at the cardiology ward is seen. This can be explained 
by the fact that most medication need checks at the cardiology ward are for the 
adherence of treatment protocols, which makes one check, while the 
pharmacists at the orthopaedic ward often checks several separate needs that 
have no superior protocol. A pharmacist at the cardiology ward will for instance 
check if an ACS or STEMI protocol is followed, while a pharmacist at the 
orthopaedic ward will check if the patient is on optimal analgesic treatment, 
needs thromboprophylaxis for immobilisation and have aspirin prescribed for 5 
weeks post-operation. 
 
The higher percentage of effectiveness and safety checks may be explained by 
the fact that drugs such as beta blockers and ACE inhibitors are started for newly 
diagnosed cardiovascular conditions, and that these needs to be titrated. During 
the titration phase tolerance and effect will be closely monitored.  
 
No significant differences were found for compliance checks, and these can 
possibly be explained by the fact that there were no difference in age between 





Change in Drug Therapy Processes 
 
There was no overall difference in the mean value of Changes in Drug Therapy 
Processes between the two wards. The distribution to the subcategory for the 
clinical shared records differed between the two wards. While the pharmacists at 
the cardiology ward performed 15.9% changes in shared clinical records of 
patient characteristics, the pharmacists at the orthopaedic ward performed 0 
changes. These changes consists of updating the allergy status on the electronic 
prescribing system when new allergies or sensitivities have occurred since last 
admission or when allergy status is undetermined. In the orthopaedic ward more 
changes in shared clinical records of drug history was made than at the 
cardiology ward. 
 
One of the pharmacists from the cardiology ward explained in the focus group 
that the doctors at TAH leaves the job of sorting drug history and updating 
allergy status to the pharmacists. Changes in shared clinical records of drug 
history largely predominates this category. 
 
Change in Drug Therapy 
 
There was almost twice as many Changes in Drug Therapy at the orthopaedic 
ward as on the cardiology ward. The difference in number of changes mainly 
involved that more drug selections were prompted at the orthopaedic ward, and 
a possible explanation to why less drug selections were prompted at the 
cardiology ward may be the same as for why there were less medication need 
inquiries there, namely the usage of treatment protocols. At the orthopaedic ward 
29.8% of DTPs were “Need for additional  medicine”, while the proportion was 
7.1% at the cardiology ward. The differences can possibly also be explained by 
the type of wards; the cardiology ward is a medical ward, and the focus on 
pharmacotherapy may therefore be higher than it is on an orthopaedic ward. A 
higher number of total checks and the need for fewer changes, may imply that 
prescribing errors have been prevented from earlier on during the admission to 
the cardiology ward. A fifth of the DTPs documented for the cardiology ward 
were in addition compliance issues. 
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The changes seen in route/dose-form at the orthopaedic ward is due to the 
comprehensive use of IV antibiotics in the post-operation phase. A number of 
drugs are also used IV at the cardiology ward. The pharmacists documented 
monitoring of this use, but did not prompt any changes for any patients included 
in the survey. Since the pharmacists were monitoring IV drug use at both wards, 
the number of changes seen prompted for at the orthopaedic ward can be 
explained by doctors that lag on changing administration form, and not by the 
lack of monitoring from the pharmacists side at the cardiology ward. A change of 
administration route in these cases were categorised into the DTP subcategory 
“Ineffective drug”, and while 2.4% of DTPs were categorised into this category at 
the cardiology ward, the proportion was 9.6% at the orthopaedic ward.  
 
42 percent of the changes in drug therapy were stopping of a drug temporarily or 
permanently. The two pharmacists that participated in the focus group from TAH 
explained this result by a new type of error that the electronic prescribing system 
(EPS) is prompting; the suspension of drugs that really should be stopped. 
Technically it is as simple to suspend a drug as to stop it on the EPS, and this 
function is seen used more than the pharmacists think is ideal. Since a 
suspended drug easily can be prescribed in error for discharge, the pharmacists 
wants to limit the use of suspensions, and usually advices the doctors to stop 
these drugs. The DTP category “Unnecessary drug” was used to categorise 
these issues, and had high proportions at both wards. 
 
Quality Assurance Descriptors, Time Perspective for Checks: 
 
A higher proportion of checks were categorised to take place during the 
monitoring phase at the cardiology ward than at the orthopaedic ward, while no 
checks were categorised as a confirmation at the cardiology ward. The inter rater 
reliability test showed that the raters commonly differed from each other when 
categorising issues into monitoring and confirmation, with the rater from the 
cardiology ward categorising issues into monitoring while the rater from the 
orthopaedic ward categorised them into confirmations. This difference can 
probably be explained by the rater not focusing on categorising checks further 
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into confirmations. When this is the case, the results from table 25 comparing the 
distribution of checks within time perspective will have no value. 
 
A high proportion of changes in Drug Therapy Processes were performed in the 
verification phase at both wards, and as seen before changes in Drug Therapy 
Processes mainly consisted of updating clinical shared records of patient 
characteristics and drug history, and it is natural that these changes are done 
when the pharmacist first meets the patient. More changes were done in the 
monitoring phase at the cardiology ward than at the orthopaedic ward, and this 
can be explained by a higher proportion of issues regarding continuity of care 
and health care team members education, activities that typically proceeds in the 
monitoring phase. 
 
Quality Assurance Descriptors, Degree of Change 
 
No differences were seen between the wards when the distribution into Quality 
Assurance Descriptors for Changes in Drug Therapy were tested. A possible 
explanation for this can be that the two biggest subcategories for these changes, 
Drug Selection and Stop Drug, combined accounted for nearly 70% of the care 
issues at both wards, and the assumption that the distribution of these changes 




A recommendation to the prescriber was made in trice as many care issues at 
the orthopaedic ward as on the cardiology ward. About 90% of the 










5.3 An electronic care plan template 
 
5.3.1 The proposed template 
 
Since only a little time was left for discussing the care plan template after 
discussing the categorisation guideline in the focus group held at Strathclyde 
28.04.08, the number of comments on the template is limited. The quality of the 
audiotape is also varying, so it was hard to transcribe whole statements. Key 
comments are therefore presented in table (?), and the analysis will be based on 
these key comments and notes taken from the group meeting at TAH 21.04.08. 
The investigator perceived that there were agreement about that the template 
have captured the information as discussed on the first group meeting, and this 
was also confirmed on a direct question in the focus group meeting. 
 
The care plan template presented here is a draft made as a Excel® document, 
so there is still work to be done before it can be tried out by clinical pharmacists. 
This project merely states what the content for such a template should be, and 
the technical issues that would arise when making software for an electronic 
template have not been looked upon. Since the final template haven’t been 
developed yet, the investigator can only assume that it will be applicable for its 
use, based on the fact that the template is developed with starting points in care 
plan templates and the Medicines Reconciliation Form which already are in use. 
The biggest intervention in this template compared to other templates that are 
used at present, will be that it is electronic. 
 
As an electronic prescribing system has both advantages and disadvantages, an 
electronic care plan template will probably also have features that are both 
favourable and unfavourable. The templates interface will for instance affect it’s 
usefulness, and this interface should be therefore be developed in association 
with the pharmacists that actually will use the template. As for all systems there 
is always the danger that functions intended to be helpful turns out not to be, for 
instance are decision support system with pop-up windows regarded as 
troublesome by some of the users and therefore ignored. A potential downside 
with inter connecting the lab result reporting system with the care plan template, 
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could for instance be that this makes the pharmacist more passive. When 
transcribing values to the care plan the pharmacist may have more time to reflect 
on this information, and this aspect of the process gets lost with the automation. 
On the other side will inter and intra linking between electronic systems reduce 
transcribing errors and save time, so a full evaluation of the electronic care plan 
template can first be made after experiences from its use have been made.  
 
Another potential disadvantage would be if the care plan structure turns out to be 
to strict. When designing the template a decision was made to omit certain part 
of the Medicines Reconciliation Form for instance, in order to exclude the 
possibility of presenting care issues other places than in the care issue section. It 
was also decided not to have a general free text box on the first group meeting 
held at TAH 21.04.08, because the investigators and the pharmacists couldn’t 
think of any instances were this would be needed. The care plan is a tool for 
structuring pharmaceutical care and documenting care issues, and the 
assumption was therefore made that all relevant problems should and can be 
presented in the care issues section. This assumption can however be proven to 
be wrong. Even though this care plan template resembles paper templates that 
already are in use, new problems could arise within an electronic interface, since 
when a paper care plan is used, it is always possible to present information on 
the back page of the sheet if no other places are applicable, and this will not be 
possible electronically.  
 
The introduction part of this paper attach weight to the importance of considering 
patient demographics such as living situation and occupation in addition to age, 
gender, weight and so on, and while the latter demographics already will be 
noted in the POE, together with a complete drug regimen, there is no space for 
presenting living situation, occupation and certain other demographics in the 
template. The idea behind this is to limit the writing of information that is not 
relevant, and promote that relevant information is presented as care issues. It is 
thereby assumed that living situation only is relevant when there is a need to 
arrange for home care and etc. At the group meeting in Ayr it was also expressed 
from the pharmacists side that tick boxes to note if the patient have home care, 
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needs an blister pack on discharge and etc, could fragment information to much 
and therefore be troublesome. 
 
When making the care plan template and developing the guideline for the 
categorisation system, the investigators hoped that the categorisation database 
could be implemented in the final template, so that this audit could then be 
repeated from time to time. If the care plan template could be directly linked up to 
a database like access, this would make it easier to this audit, since the 
investigators wouldn’t have to plot all the data in to the data base manually, and 
instead just concentrate on the categorisation part. The use of such a system 
would however be limited since an audit such as this still is a lot of work, and 
doubtfully wont be performed routinely. In the focus group held at Strathclyde 
28.04.08 one of the key comments confirmed this, stating that “Connecting the 
categorisation system to the care plan template, would make the date base 
complex”. 
 
It is however possible to do smaller audits by using data from an electronic care 
plan template. Subjects for audits can i.e. be how well the pharmacists 
documents sources for drug history, how often they document that they have 
asked the patient for use of herbal and OTC drugs and etc. A spare tick box 
could also be used occasionally for audits where data can’t be gathered directly 
from existing sections, for instance the pharmacists can be asked to record it by 
ticking the box, every time they educate a patient about drug use or do a generic 
switch according to local formularies. Electronic data gathering reduces the 
workload when processing the information. 
 
5.3.2 There is a great potential for an electronic care plan 
 
The investigator hope to have showed what a great potential there is for 
developing an electronic care plan template. Both clinical pharmacy and 
electronic prescribing are here to stay, and the development of an electronic care 
plan template will therefore be a good investment. 
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A problem that was highlighted in the focus group meeting at Stratclyde, was that 
there is little interest for the use of care plans England at the moment. The four 
other hospitals that use software from the same producer as TAH and have full 
electronic prescribing, are English, and the soft ware producer therefore don’t 
see a marked for an electronic care plan template. At the group meeting held in 
Ayr one week prior to the focus group, it was emphasised that the most important 
thing to ask the software supplier for, if only to ask for one thing, is a table for 
presenting care issues. There was agreement on that a table for presenting 
issues would be of great help, and that it should not be a lot of work for the 
software suppliers to have this within POE.   
 
An electronic care plan template would also be a valuable learning tool for 
pharmacy students, and software for such a potential template could also be 
used at the universities when training students in documenting pharmaceutical 
care. The need to train pharmacists in care planning, including the use of 
categories for describing care issues was empathised in the focus group 
meeting, as both documentation and structured care planning are very important 







The categorisation system and the guideline that was developed were evaluated 
based on the investigators experience with it and in a focus group meeting. While 
check, changes and DTP categories were practical achievable to use, 
suggestions were made to how the Quality Assurance Descriptor system could 
be improved. It was empathised how important it is to use intuitive terms when 
describing pharmaceutical care. Cohen’s Kappa was tested for the system and it 
was confirmed that the Quality Assurance Descriptors subcategories is 
ambiguous. Inter rater agreement was found to be highly good for the 
subcategories of check, changes and DTPs. 
 
The quantitative content analysis showed certain differences between the 
provision of pharmaceutical care at the cardiology ward and at the orthopaedic 
ward. A higher mean value of care issues per patient was found at the cardiology 
ward, and this can be explained by the fact that more drugs are started at the 
cardiology ward that needs close monitoring in the titration phase. The more 
extensive use of treatment protocols at the cardiology ward can explain that a 
lower number of changes in drug therapy is seen at this ward than at the 
orthopaedic ward. A new type of error that the electronic prescribing system 
promotes is that drugs often are suspended in stead of stopped. 
 
A proposal for what an electronic care plan template should and can contain was 
made, based on feedback from the clinical pharmacists at Ayr Hospital. There is 
a great potential for developing such a template within the electronic prescribing 
system used at Ayr Hospital today; a template will help the pharmacists 
document pharmaceutical care in a structured way, and functions that save the 
pharmacists time and increases the quality of the care planning can potentially 







Appendix 1. Time spent on pharmaceutical care processes at the medical 
cardiology ward and the coronary care unit 
 




















The pharmacist reviews 
medical records and take 
relevant medical history. This 
serves as a starting point for 
initiating a care plan 
 
The pharmacist checks: 
• GP referal letter/calls 
GP 
• Speaks with 
patient/relatives 
• Community pharmacy 
• Prevoius dc letter 
• PODs if brought in 
The pharmacist usually 
checks with two or more 



















The pharmacist transcribe 
current drug regime if this is 
not al ready done 
 
The pharmacist checks for: 
• Indication for all the 
drug therapies 
• Right medicine 
• Right dose 
• Dosing intervall 
• Course duration 













3-4 patients are 
admitted daily to 
the ward 
 
87.8 % of the 
included patients 
had a care plan 
already started on 
admission, and 
already had their 
drugs on 
admission 
reviewed prior to 
transfer to the ward
 
Coronary care unit:
1-2 patients are 
admitted daily to 
the ward 
 
6.3 % of the 
included patients 
had a care plan 
already started on 
admission, and 
already had their 
drugs on 
admission 
reviewed prior to 
transfer to the ward
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The pharmacist reviews care 
plans that already are started 
for transferred patients, and 
all care plans with a review 
date that day 
 
All care issues identified and 
that are dealt with through 
monitoring or simple changes 
in the drug regime done by 
the pharmacist (ex generics, 
dosage form etc) 




Care plans where 
usually reviewed 
every 2nd or 3 rd 




Care plans where 
usually reviewed  
every weekday 
during the survey 
period 
4 Speaking with 
Dr (and other 
health care 
workers) 
All care issues that requires 
pharmacist to confer with 
Dr/health care workers, and 
all questions that are passed 
from Dr/health care workers to 
pharmacist 
10-15 min 
per day for 
review of 
changes. 












Explaining to the patient why 
he/she needs drug therapy 
and the effect/side effects the 
medication may have 
















the care plan 
Making sure that patients are 
followed up, ex by arranging 
for warfarin clinic, notifying 
community pharmacy of 
changes in drug regime and pt 
discharge 
 
Documenting identified care 
issues 
Documenting actions that are 
done and that need to be 
done in the care plan. 
Documenting outcomes 
Writing information for the 
dispensary in the care plan 
5 min per 
pasient 










TTA: The pharmacist checks 
for: 
• Indication for all the 
drug therapies 
• Right medicine 
• Right dose 
• Dosing intervall 
• Course duration 





• Non formulary 
prescribing 
• Sedatives etc 
Dc letter: The pharmacist 
checks for: 

















Appendix 2 Guideline for categorisation of pharmaceutical care issues before the 
altering 
 
DATA COLLECTION FOR MSC PROJECT 
 
 









Medication need inquiry 1 
Effectiveness inquiry 2 
Safety inquiry 3 
Compliance inquiry 4 
Formulary adherence inquiry 5 
 
 
CATEGORISATION OF CHECKS 
 









Patient comprehension  
Patient agreement  
and participation 
 
Patient characteristics  
Drug history  
Continuity of information/ 
care between clinical settings
 
Drug selection  
Daily (total) dose increase  
Daily (total) dose decrease  
Route/dose form  
Dose interval/timing/duration  
Drug use precautions e.g. 
potential interactions 
 




CATEGORISATION OF CHANGES 
 
Type of change Code
Modification MOD
Adjustments ADJ 
Reviews (prompt a review) REV 
 
 
CATEGORISATION OF DRUG THERAPY PROBLEMS (DTP) 
 
DTP Code
Unnecessary drug therapy DTP1
Additional drug therapy needed DTP2
Inappropriate drug DTP3
Dosage too low DTP4
Adverse drug reaction DTP5




PHARMACEUTICAL CARE ISSUE DEFINITIONS 
 
 
Definitions of categories for recommended or implemented changes 
 
Adjust  - Adjustment is a change to the implementation of the treatment plan to 
individualise or optimise prescribing/administration/concordance. Adjustments 
occur as a result of monitoring actions. 
 
Review - a prompted review leads to a medical review of the patient’s treatment 
and their needs (due to inadequate response/unwanted drug effect/ change in a 
patient’s needs). 
 
Modify A modification is any change to the implementation of the treatment plan 
which is not an adjustment or review (including response to errors in 




Definitions of categories for recommended or implemented checks 
 
Verify - a verification is a check to exclude an initial error in 
prescribing/conditions of administration. 
 
Confirm - a confirmation is a written record of a patient/laboratory check that 
confirms medication has met expectations (in terms of defined goals for a given 
stage of treatment). 
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Monitor - monitoring  is a periodic patient/laboratory check to ensure satisfactory 
implementation of the treatment plan and that further adjustment is not required. 
 
Normally a single care issue would address a single drug therapy problem (DTP). In the 
case of a care issue seeming to address more than one DTP, then the care issue may 
best be resolved into multiple care issues. There are two exceptions to this that we are 
prepared to recognise as common examples 
 
1. Checks of Dosage (Verification or Monitoring)  to exclude both too high 
and too low a dose will need to have three DTP categories (DTP4, DTP5 and 
therefore DTP6). This can only be avoided by recognising such checks as TWO 
care issues; a check for safety of the dose (and therefore DTP 5 + DTP 6) and a 
check for effectiveness of the dose (DTP 4) 
2. Checks for dose-related unwanted drug effects (Monitoring) will need 
to have two DTP categories (DTP5 and DTP6). This dual designation will carry 
an advantage in allowing the number of dose related ADRS (classed as DTP5 + 
DTP6) to be differentiated from non dose-related (DTP5 only). 
3. Drug history checks are classified as addressing the prevention of Non-
Compliance (DTP7) to acknowledge the fundamental purpose and so avoid 
many and various other inconsistent interpretations. The DTP code DTP7 is also 
used when a change is made that communicates the discontinuation of a drug 
during transfer of care. 
4. Where checks of dosage involve initial check (verification) of dose 
and further check (monitoring), for instance of plasma concentration or clinical 
effect, then the separation of the designation of the actions requires the 






Appendix 3 Data gathering: Free text version of care plan for patient 6-27 
 
CARE PLAN REVIEW DAILY 
 
PC  








Pt sheet - verapamil (Vertab) 240mg od, ipratropium 0.5mg and salbutamol 5mg nebs QID, 
Salbutamol MDI 2puffs prn, flixotide 250 One dose BD, Serevent 50 One puff BD, ciprofloxacin 
500mg BD and prednisolone 50mg mane (both now stopped) 
ECS - does not state verapamil or flixotide, Others above mentioned. Serevent dry powder = 
accuhaler. Also states erdosteine 300mg BD. 
Phoned GP-  Confirmed verpamil 240mg mr od, fluticasone 250 MDI one puff BD last had March 
07. Erdosteine first prescription Jan 08 - 300mg BD also had in Feb 08. Aspirin 75mg od started 
Jan 08. (Pharm 1) 19/2 
 
Bloods 
19/2 u 8.8 Crt 90 K 4.6 Hb 13.3 wcc 12.5 plts 239 JS 
20/2 Cr 95 wcc 12.5 CRP 31  
 
Issues 
*1. Not well enough to use inhalers or speak today. Check need for fluticasone (Pharm1) 19/2  
 
*2 Not well enough to take many orals today - although managing. Will manage the ciprofloxacin. 
Currently prescribed carbocisteine not erdosteine. Erdosteine N/F. Have now confirmed with GP 
review tomorrow switch or leave as carbocisteine. (Pharm1)19/2  Erdosteine intended for 10 day 
course only. Would have been nearing end of this when admitted. Left as carbocisteine. Also 
review if aspirin to start tomorrow. (Pharm 1) 19/2 Note left in medical notes (Pharm 2) 20/2 
 
3. Salbutamol nebs dose reduced to 2.5mg PRN intentionally and ipratropium increased to 6 
times daily confirmed with nurse since tachycardia. (Pharm 1) 19/2 
 
4. Home nebuliser (Pharm 1) 19/2 
 
*5 Monitor antibiotics switch to oral and inf markers (Pharm 1) 19/2 
  Switched to oral - monitor duration   27/2 (Pharm 3) 
 
*6 Last night svt/paf - Electrical cardioversion on heparin inf - prescribed as charted on EP. Dr 
Rose has asked for cardiologist review of antiarrythmic - monitor heparin and watch for 
antiarrythmic change. Now changed to amiodarone -  check notes tomorrow - verified (Pharm 
1) 19/2 Changed to amiodarone on Dr (X)’s advice (Pharm 2) 20/2 









Data gathering: Care plan documented in template for patient 6-27 
 
Only issues contributed to by pharmacist 3 is included in this version of the care 






PATIENT PAPER PROFILE 
 
PATIENT DETAILS   
Number 6-27 Sex M Age 60 
Height 5 ft 6 Weight 10 st 2 BMI  Ability to self 
medicate 
Allergies/Sensitivities  Type of reaction  
NKDA - 
Social History  
Married, lives at home 
Retired 
No alcohol, smokes 5 cpd 
 
PATIENT STAY Presenting 
Complaints 
Notes 
Admitted/Transferred from     Med high 
care 
Date of admission to ward 5    
First seen by pharmacist 
At ward 5 
 
Date of admission to ward 6   20.02 
First seen by pharmacist 
At ward 6 
27.02 
Discharge date  28.02 
















RELEVANT DRUG HISTORY 
Date Problem Description Medication on 
admission 
Comments 
 Paroxsymal AF Verapamil (Vertab) 
240mg od 





and Salbutamol 5mg 
nebs QID, Salbutamol 
MDI 2puffs prn, 
Flixotide 250 One 
dose BD, Serevent 50 
One puff BD 
Erdosteine 300mg BD
Was treated with 
ciprofloxacin 500mg 
BD and prednisolone 
50mg mane on 
admission also (both 
now stopped) 
 







RELEVANT NON DRUG 
TREATMENT 
 

















Pt is on 
antibiotics 
switched to oral 
from IV 25.02 
27.02 
MC 










Counsel pt 27.02 
MC 




REVIEWS      
Review Dates 
(Planned) 
28.02       
Review Dates 
(Actual) 
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Pharmaceutical care is delivered by a team of health care professionals. The 
focus of the categorisation system described here is pharmaceutical care 
contributions made by the pharmacist within that context.  
 
To better comprehend this guideline it is important to have an understanding of 
how the pharmacist provides pharmaceutical care. This is a cyclical process and 
will briefly be described here. 
 
The pharmacist initiates this process by gathering relevant information about the 
patient’s drug treatment and medical history, which reveals pharmaceutical care 
issues. The pharmacist handles the care issues by doing checks leading to three 
different results:  
1. The care issue is found not to be an actual or potential drug therapy 
problem that needs further follow up at this point. 
2. There is an identified need to take action(s) to prevent future drug therapy 
problems. 
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3. A drug therapy problem is identified and there is a need for a change in 
the patient’s drug therapy at this point . 
 
 
2 Definition of a pharmaceutical care issue 
 
A pharmaceutical care issue is an identified concern regarding a potential or 
actual drug therapy problem. A drug therapy problem is patient specific, and so 
does not include non-adherence to local formulary choices that are based on 
cost controls. 
 
3 The categorisation system – a short summary 
 
The categorisation system is developed to describe pharmaceutical care. This is 
done by analysing each care issue and assigning them into categories. This 
categorisation process provides a basis for quantitative description of the 
pharmacist’s contribution to pharmaceutical care, which makes it possible to 
compare pharmaceutical care provided by a pharmacy service across different 
settings. 
 
Each care issue is described according to a triangularised system which consists 
of multiple categories. The advantage of combining different categorisation 
systems into one triangularised system is that the categories supplement and 
support each other, and therefore they capture the different dimensions of the 
pharmaceutical care issues.  
 
Each care issue is categorised in three such dimensions; 
 
(1) As either a Check or a Change1; where a Change may be a Change in the 
Drug Therapy Process or a Change in Drug Therapy, depending on the outcome.  
 
The care issue is further categorised into: 
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(2) Quality Assurance (QA) Descriptors1, which indicate a care issue’s position in 
the process of delivering pharmaceutical care. If the care issue is a Change in 
Drug Therapy this category also describes the extent of the change made.  
 
The third dimension in the system is  
(3) Drug Therapy Problem2 and only a care issue identified as a Change in Drug 
Therapy will be categorised as such. 
 
If the outcome of the care issue is unknown, the care issue is incomplete and can 
not be categorised in the categorisation system.   
 
Table 1. Categorisation set-up 
Quality Assurance 
Descriptors 













       
 
The different parts of the triangularised system with its categories are described 
below. 
 
4 ‘Check’ and ‘Change’ categories 
 
4.1 Checks  
 
When a care issue is identified, the pharmacist has to perform checks in order to 
detect required actions to prevent future drug therapy problems or required 
changes in drug therapy addressing actual drug therapy problems. If the check 
leads to neither an action nor a change the care issue is categorised as a Check. 
A care issue categorised as a Check is assigned to one of four subcategories; 
“medication needs”, “effectiveness”, “safety” or “compliance”, based on the 
reason for the inquiry as summarised in table 2.  
 
The pharmacist’s intentions behind making the check constitute the basis for the 
number of care issues identified and for the categorisation of the identified 
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check(s). A check performed by a pharmacist may be an inquiry which addresses 
both effectiveness and safety, (for instance when INR or lying/standing blood 
pressure is measured). In that case the care issue will be divided into two care 
issues; one check of effectiveness and one check of safety.  
 
If the pharmacist recommends making a change in the patient’s drug therapy in 
order to resolve or prevent a drug therapy problem, but the responsible 
prescriber either doesn’t agree with the change or agrees but forgets to make it, 
the care issue will be categorised as a check because no change in the patient 
drug therapy is carried out. 
 
 






The category Change is divided into two types of subcategories; Change in Drug 
Therapy Process and Change in Drug Therapy. The Change in Drug Therapy 
Process category includes care issues relating to changes in the care process, 
and this means that the impact of the outcome often is hard to determine or is too 
speculative to lead to a Drug Therapy Problem category. The Change in Drug 
Therapy category, on the contrary, includes changes related to drug therapy, 
non-compliance and prescription, where the outcome can be assigned a 
recognisable Drug Therapy Problem category. 
 
Even though all changes are inevitably the result of a check, such checks will not 
be categorised since their relevance is superseded by the resulting change. The 
care issue will be adequately described by the resulting categories of Change, 
Quality Assurance Descriptors and Drug Therapy Problem. 
Check Code 
Medication need inquiry MED 
Effectiveness inquiry EFF 
Safety inquiry SAFE 




5 Change in Drug Therapy Process 
 
The pharmacist performs different actions to address the pharmaceutical care 
needs of the patient. Not all of these actions result in a change to the patient’s 
drug therapy. Nevertheless it is important that these actions are quantified, as 
they comprise a great part of the pharmacist’s delivery of pharmaceutical care.  
 
The category Change in Drug Therapy Process describes the actions the 
pharmacist performs to prevent potential drug therapy problems and to identify 
actual drug therapy problems (Table 3).  
 
Table 3 Change in Drug Therapy Process categories 
Changes made to Code 
Clinical (shared) record of patient characteristics CHAR 
Clinical (shared) record of drug history DH 
Continuity of information/care between clinical settings CONT 
Level of patient monitoring MON 




5.1 Explanations of the Change in Drug Therapy Process subcategories 
 
Clinical (shared) record of patient characteristics  
This and the next subcategory describe actions that may affect the patient’s drug 
therapy since his/her treatment is based on available patient information. For 
instance, it is important to note in the patient’s record if he/she is allergic to 
penicillins, in case an antibiotic treatment is required later.  These actions help to 
avoid potentially preventable drug therapy problems in the future.  
 
If the pharmacist corrects or up-dates the patient’s shared records, for instance 
adds two drugs that the patient is allergic to, this will be recognised as one care 
issue. If drug therapy changes have to be made as a result of the corrected or 
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up-dated record, this is recognised as one care issue for each drug that is 
changed.  
 
Clinical (shared) record of drug history  
When the pharmacist takes the drug history, discovers errors in prescribing on 
admission and proposes/makes a change to the drug therapy based on this, this 
is interpreted as one pharmaceutical care issue for each drug that is changed.  
 
Continuity of information/care between clinical settings 
This subcategory encompasses the actions the pharmacist undertakes to ensure 
continuity of care and transfer of relevant information between clinical settings, 
including making new arrangements for the patient with other health care 
institutions.  The clinical settings include all healthcare institutions that have 
responsibility for the patient’s health care.  
 
A number of care issues might be included globally in a document transferring 
the patient’s care between clinical settings. If the pharmacist prepares or advises 
on the document, but doesn’t follow-up on the recommendations made, that 
would be a single care issue. This is because the care issues have unknown 
outcomes, and therefore can’t be categorised. We can only categorise the action 
of the pharmacist in terms of making the recommendation. 
 
Level of patient monitoring 
Some care issues can result in the identification of a need to increase/improve 
patient monitoring.  This increased/improved patient monitoring doesn’t have to 
be performed by the pharmacist, but he/she must initiate it or advice about it. 
 
Health care team member(s) education / information 
This subcategory describes care issues where the pharmacist contributes by 
providing information or education to other health care personnel regarding the 








6 Change in Drug Therapy 
 
A care issue that is categorised as a Change in Drug Therapy (Table 4) includes 
changes to;  
• the drug therapy of the patient 
• the patient/patient’s carer understanding of the drug therapy or disease  
• the patient’s adherence to their treatment plan, that is patient compliance   
 
Pharmacists, unless they are acting as prescribers themselves, will in most cases 
make a recommendation to the patient’s prescriber, and the care issue will be 
categorised as a Change in Drug Therapy if the recommendation is accepted and 
carried out.  
 
The outcome of changes made to the patient/carer understanding/compliance is 
hard to measure, but it is included in the Change in Drug Therapy subcategory 
because it can be categorised as a Drug Therapy Problem, and it can be viewed 
as a categorisation of the intention of the effort made by the pharmacist. 
 




7 Drug Therapy Problems (DTP)  
 
The categories of Drug Therapy Problems are those defined in the book 
Pharmaceutical Care Practice – The Clinician’s Guide 2 by Cipolle et al. The 
categories are given examples here to include a broader range of care issues. In 
Changes made to: Code 
Drug selection (starting new or changing drug) SEL 
Dose  DOSE 
Route/dose form FORM 
Dose interval/timing INT 
Duration DUR 
Stop drug temporarily/permanently STOP 
Patient or Carer Level of Education (Understanding/Compliance) EDU 
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addition they are modified to enhance the correlation between the heading of the 
DTP subcategories and the type of care issues included in them. An additional 
subcategory Unclassified has been added in order to categorise care issues 
where the change is not patient specific. For instance due to non-adherence with 
local formularies and with only cost-control implications, rather than medication 
safety or effectiveness. 
 
Only Change in Drug Therapy types of care issue will be categorised into Drug 
Therapy Problem categories. The combination of the Change in Drug Therapy 
subcategory and the Drug Therapy Problem subcategory will describe the nature 
of the change made to the patient’s drug therapy, see table 5 below. 
 
Table 5. Categories and common causes of drug therapy problems 
Drug Therapy 
Problem 
       Common causes of drug therapy problems 
 

















There is no valid medical indication for the drug therapy at this tim
 
Multiple drug products are being used for a condition that 
requires fewer drug therapies 
 
The medical condition is more appropriately treated with non 
drug therapy 
 
Drug therapy is being taken to treat an avoidable adverse 
reaction associated with another medication 
 
Drug abuse, alcohol use, or smoking is causing the problem 
 
The duration of therapy is too long 











A medical condition requires the initiation of drug therapy 
 
Preventive drug therapy is required to reduce the risk of 
developing a new condition 
 
A medical condition requires additional pharmacotherapy to 
attain synergistic or additive effects 
 
The duration of drug therapy is too short to produce the desired 
response 
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Table 5 (cont.) Categories and common causes of drug therapy problems 












The drug is not the most effective for the medical problem 
 
The medical condition is refractory to the drug product 
 
The dosage form of the drug product is inappropriate 
 
The drug product is not an effective product for the indication 
being treated 
 
The time of dosing or dosing interval is not the most effective 
 
Route of administration is not the most effective 
 







The dose is too low to produce the desired response 
 
The dosage interval is too infrequent to produce the desired 
response 
 
A drug-drug/food/lab/disease interaction reduces the amount of 
active drug available 
 




















The drug product causes an undesirable reaction that is not 
dose-related 
 
A safer drug product is required due to risk factors 
 
A pharmacodynamic drug-drug/food/lab/disease interaction 
causes an undesirable reaction that is not dose-related  
 
The dosage regimen was changed too rapidly 
 
The drug product causes an allergic reaction 
 
The drug product is contraindicated due to risk factors 
 
The time of dosing or the dosing interval is not the safest. 
 
Route of administration is not the safest 
 









Dose is too high 
 
The dosing frequency is too short 
 
A drug-drug/food/lab/disease interaction occurs resulting in a 
toxic reaction to the drug product 
 
The dose of the drug was administered too rapidly 
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The patient prefers not to take the medication 
 
The patient does not understand the instructions 
 
The patient forgets to take the medication 
 
The drug product is too expensive for the patient 
 
The patient cannot swallow or self-administer the drug product 
appropriately 
 
The drug product is not available for the patient 
 










8 Quality Assurance Descriptors 
 
A patient’s drug treatment can be regarded as a cyclical process, which 
encompasses the design, delivery and evaluation of the treatment plan according 
to expectations predefined by clinical standards. Figure 1 shows the pharmacist’s 
systematic role as a contribution to increase the quality of this cyclical process. 
At each step during the cycle the pharmacist (and other health care team 
members) is in a position to perform checks to confirm the quality of the delivery 
of the treatment plan. Whenever the checks reveal deviations from the 
expectations established in the plan, changes to the treatment or the treatment 
plan are proposed or executed. This process can be viewed as a feedback loop, 
where changes are integrated into the cycle.  
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Figure 1 Pharmaceutical care model  
 
 
The Quality Assurance (QA) Descriptors identify both the points in the feedback 
loop at which the care issues (the Checks or Changes) are implemented and the 
extent of changes in drug therapy. To emphasise what they describe, the 
subcategories for QA Descriptors are designated Time Perspective and Degree 
of Change. 
 
All care issues will be categorised according to the QA Descriptor Time 
Perspective. This QA Descriptor adds a time perspective in the treatment cycle to 
the triangularised system. If the care issue is a Change in Drug Therapy it will be 
categorised according to the QA Descriptor Degree of Change as well. This QA 
Descriptor describes the extent of the change made (Table 6).  
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Table 6. Summary of which care issues are categorised into the two 
different Quality Assurance Descriptors subcategories 
Quality Assurance Descriptors 
Time Perspective Degree of Change 
 
Check 
Change in Drug Therapy Process 
Change in Drug Therapy 
 
Change in Drug Therapy 
 
 
8.1 Time Perspective 
 
The subcategories of Time Perspective are Verification, Monitoring and 
Confirmation, see table 7.  These subcategories relate to the point in the system 
feedback loop where the initial check that identified the care issue was made. 
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Table 7. Categorisation of checks according to quality system feedback loop 





medications in the 
proposed treatment 
plan 
VER Checks at the start of the treatment to make sure that, 
for each medicine, the patient: 
- is on the right medicine 
- is on the right dose 
- is not on unnecessary medication 
- doesn’t have any new needs for 
additional medication 
- is not receiving a combination of 
interacting medicines 
- understands how to take their 





treatment is appropriate 






Checks as treatment continues which should ensure 
that, for each medicine, the patient: 
- is on receiving medication as intended 
- continues to be on the most suitable 
dose 
- has no symptoms of 
unwanted(adverse) effects 












Confirmation and documentation to identify that 
medication is: 
- resulting in expected effects on the 
patient's condition 
- not failing to control condition 
- not producing unwanted effects 
requiring clinical review. 
 
Verification  
A ‘Verification’ is either done at the start of a new patient treatment or when the 
pharmacist first assesses the patient and the medication, see table 7. 
 
• In chronic disease management, for instance by a clinical pharmacist at an 
outpatient clinic or a community pharmacy, ‘Verification’ is done at the first 
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episode of care with the pharmacist. That may or may not be at the start of 
the patient’s treatment but must be undertaken for the pharmacist to 
assure himself or herself that the proposed treatment plan is suitable for 
the patient’s need.  
 
• When the patient is seen in an interim episode of care interrupting chronic 
disease management, for instance by a clinical pharmacist at a hospital 
ward during an acute admission, the verification category will relate to 
when the pharmacist first saw the patient. ‘Verification’ of the patient’s 
drug treatment is done at admission, or when a new drug is started. All 
checks at this point in care should be categorised as ‘Verification’ even if 




‘Monitoring’ is done during the patient’s treatment (during the delivery of the 
treatment plan) with the goal of assuring the medication process is being 
implemented as intended and within general expectations of signs of benefits 
and absence of adverse effects, see table 7. 
 
Confirmation  
‘Confirmation’ is an evaluation of the patient’s treatment to assure that expected 
effects are achieved, adverse effects avoided or suitably managed and that the 
condition is treated optimally, see table 7. This category usually applies to care 
issues concerning the continuing evaluation of a chronic disease, an acute 
exacerbation of a chronic disease, or an acute episode of disease 
 
8.2 Degree of Change 
 
The Degrees of Changes are Adjustment, Modification and Prompt a Review, 
see table 8. These three subcategories describe the extent of the change made. 
Both Adjustment and Modification may take place at the start or during 
treatment, while Prompting of a Review results from a failure in treatment and 
so only occurs after a trial period of treatment, see figure 1. 
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Since it is difficult to distinguish between the extents of changes made in Change 
in Drug Therapy Process, only Change in Drug Therapy will be categorised into 
Degree of Change.  
 
Table 8. Categories of changes according to the extent of the change in the 
quality system feedback loop 
 
Degree of Change Code
Adjustment ADJ 
Modification MOD 
Review (prompt a review) REV 
 
If a Check leads to a Change, the Time Perspective (i.e. at what time in the 
treatment cycle the check is done) will influence the choice of the subsequent 
Degree of Change. As seen in figure 1 and table 9, a Verification can lead to 
either an Adjustment or a Modification. A Monitoring issue can only lead to an 
Adjustment. If a need for a bigger change in the treatment is identified, a 
Confirmation of the whole treatment of the patient is needed before a decision 
to either ‘modify’ or ‘review’ the treatment can be made. A Confirmation can 
lead to either a Modification or a Review, depending on the outcome of the 
‘confirmation’. 
 
Table 9. Categories of changes according to the time aspect in the quality 
system feedback loop, linked to preceding check 
 
Time Perspective Code Degree of Associated Change 
Verification VER ADJ MOD 






Adjustment is defined as a recommended change to patient behaviour, 
treatment regimen or process of continuity of care that individualises 
pharmaceutical care within the agreed treatment plan. ‘Adjustments’ are 
anticipated within the protocol/clinical management plan, and the regimen is not 
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markedly changed to an alternative treatment regimen. Most supplementary 
prescribing decisions made by pharmacists would probably fall into this category. 
 
Modification 
Modification is a change to the patient treatment that is not anticipated and 
leads to a change of the patient’s treatment plan.  
 
Prompt a Review    
A Review is a re-assessment of the patient’s treatment, and leads to a change in 
the expectations defined by clinical standards i.e. change in the expectations to 
the outcome of the treatment. Because the pharmacist is not able to review the 
treatment alone, but has to recommend a review to the patient’s main prescriber, 
the qualified term category is termed ‘Prompt a Review’. ‘Prompt a Review’ is 
done as a part of the evaluation of the patient’s treatment. This will be done more 
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Appendix 6 Transcribing of focus group 
 
Focus group, key points 
 
Question:  
What is your first impression of the guideline? 
Is it possible to use the system after reading the guideline? 
Comments:  
I think the concept of time perspective is a little bit unfocused (SH) 
I find it a bit complex, reading it (LS) 
I think checks and changes, that’s fine. But if you are actually modifying or 
adjusting things, or confirming and verifying things, that means two different 
things? You would need to know what language to use in this context (LS) 
I agree with that. Reading it through, initially I got the whole check and change 
thing. But then, I had to read it three times to understand the range of it (KW) 
That could possible translate into problems with inter-rater reliability (LS) 
 
Topic: 
Definition of a care issue when categorising 
Comments: 
I’m not aware of any training courses on documentation that is provided by the 
NHS. (SH) 
The thing is, quite usually the pharmacist would write down things and not have 
the time to follow that up (LS) 
 
Question: 
We’ve divided the changes category in two: 
Changes in Drug Therapy Process, and  
Changes in Drug Therapy, 
and we would like to have your thoughts about a division like that. 
It was explained that giving a health care workers information for a patient related 
problem is a change in Drug Therapy Process 
Comments: 
A lot of the time we give information about how to give i.v. infusions. If something 
is a bit different we often put that on the care plans and also in the system. I don’t 
know if that also would, I guess it doesn’t really fit into changes in drug therapy 
does it? Because, you are not actually changing anything (KW) 
I would just write it on the drug chart, I would never write that in the care plan 
(LS) 
It’s not a change in the drug therapy process, it is the drug therapy process 
(…)so I’m just wondering if we should….actually call these changes? (CF) 
A way of thinking about it as contribution to the drug therapy process. (CF) 
So would that work then? Under the general heading of changes you’ve got 
contributions to drug therapy processes and changes in drug therapy (SH) 
General agreement can be heard. 
It will still be classified under the overall changes. Cause you can’t avoid that 
unless you say this is neither a check or a change, it is something else. (SH) 
And what about under changes in drug therapy ’patient or carer level of 
education’. Is that really changing drug therapy? (KW) 
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I think there is a understanding in Cipolle and Strand that there is a section that 
changes that should be drug therapy problems because patient is being unable, 
having problems understanding…. (CF) 
 
Question: 
Distribution of care issues in the sub categories of checks varies, can this be 
explained? Is it expected? 
Comments: 
The expected compliance is quite high in care of the elderly, it is not really that 
surprising in all (LS) 
 
Topic: 
Documentation of checks 
Comments: 
the pharmacist, they are not documenting everything they do (CF) 
I think there is a journey to be made in getting more consistency in the 
documentation made, and that people can decide for them selves when they  get 
exposed to other peoples practice (SH) 
 
Question: 
Distribution of care issues in the sub categories of Drug Therapy Processes 
varies, can this be explained? Is it expected? 
Comments: 
I think the clinical, sort of shared record, drug history, it probably so high on the 
Ayr side because the medical staff very much leaves that up the pharmacist, 
whether that’s right or wrong, to sort out the drug history and  to transcribe 




Documentation of continuity of care 
Comments: 
It’s actually medical, legally one of the things that you would want to make sure 
was documented. It shows that you have all the informations passed on. (SH) 
 
Question: 
 Do you think there is a need for the duration subcategory, you can see that we 
have not used it, but numbers in this category were small 
Comments: 
That’s a surprise as well (LS) 
It is so that we usually talk about duration of therapy (CF) 
We have categorised everything about duration as stop drug or start drug and 
not as duration (KJH) 
I think there is a overlap here, and the definition potentially needs tidying up. (CF) 
You probably would want to have that in there, and call them both stop drugs, 
and have division between stop the duration and stop for drug therapy problems 
(CF) 
A problem with the electronic prescribing system is that drugs are suspended in 
stead of stopped, that generates extra care issues(KW) 
So duration is a change of the length of the course, that is more a subtle (SH) 
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Would the stop drug category be split into two, so that the duration is qualified 




Is there a need for the eight Drug Therapy Problem category (unclassified DTP), 
where change to formulary can be categorised? 
Comments: 
This is a standard categorisation system and so I don’t think we want to change it 
without talking to the authors (SH) 
I would say if someone is on a non-formulary drug that would be a care issue, 
and it’s something that we do spend time on (LS) 
to what extent you want to separate out impact on cost and impact on patient’s 
symptoms? (SH) 
If you’ve got a category called unclassified it would just be a bin, people would 
just put anything in it (…) call it something a little bit more specific (LS) 
 
Question: 
 Do you think interactions should be integrated into the system? 
Comments: 
similarly the patient interview is potentially going to capture patient side effects 
and patient non-compliance. So then you would have different scenarios that sort 
of prompting the patient, no the pharmacist to pick up various issues. (CF) 
I think it is the outcome you’re writing down. (GJ) 
I wouldn’t routinely write down checking for everything. (LS) 
I wouldn’t write down a drug interaction (CF) 
 
Question: 
 Should recommendations be implemented into the system? 
Comments: 
I think that can be useful, it depends on what you are going to do with that (LS) 
 
Question: 
Do these categories describe the pharmaceutical care delivered? 
Comments: 
Obvious you would get documented problem, individual practice is various at the 
moment. (SH) 
General agreement from the participants 
 
Question: 
Or we could ask, if there are any categories you would like to see or that are 
missing so far? 
Comments: 
I think you got the basis of a degree of describing a lot of the activity of 
pharmaceutical...pharmacist contributions to care (…)There’s a quite a difference 
between Ayr and Glasgow (CF) 
So, electronic prescribing brings in problems of it’s own. That’s an interesting 
finding. (CF) 
Actually, we need to go back to our service to make sure (…) It’s a new sort of 
error, to suspend drugs (GJ) 
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It’s useful for a pharmacist to see as well (…)You need to start to think is that 
because of my patient case load, or is it because that’s something I don’t do 
often enough? (LS) 
I’m not writing up all I do (CF) 
No, I know. I have no chance to do it either (GJ) 
 
Topic: 
Quality Assurance Descriptors, Time perspective 
Comments: 
You got problem (…) we have to swallow the idea verification, monitoring and 
confirmation (…) now you are asking  people to use the same terms to explaining 
changes and maybe what we are talking about… different..times in…treatment 
cycle (SH) 
Verification…..which mean…….you lost me completely (GJ) 
if you say it happen at the design stage or the delivery stage or the evaluation 
stage. Could you do that? Then you avoid the duplication of using the same word 
(LS) 
you probably have more confirmation checks than you are actually documenting 
(CF) 
I think you can do what LS suggested just redescribe …what you were attending 
to do to put the changes into design, delivery and evaluation (…)we don’t have 
an agreed language….and the language is very important (SH) 
 
Topic: 
Quality Assurance Descriptors, Degree of Change 
Comments: 
I’m surprised there were not many reviews, generally. (SH) 
Maybe the patients are,  I just think that cardiology has quiet short stay. There 
are also sort of simple treatments, treatments as per, after a set of guidelines. 
(KW) 
adjustments that were doing routinely (…) but that would give you quit a lot of 
insight into opportunities of pharmaceutical prescribing. (SH) 
I think if we had a way of separating the modifications that..were documented in 
the design stage as opposed in the evaluation stage…cause you got two 
categories there..that that would also give you interesting, new information about 
whether the doctors or the prescribers on the ward and.. they get)..ehh.. what 
they’re prescribing in a prompted way..because if the modifications are beeing 
made at the design stage.. I think that the pharmacists is affecting some changes 
early on. (SH) 
you want to be correct early on  to prevent doses totally wrong, (GJ) 
 
Question: 
Do you think there is a difference in opportunity for making  changes when you 
do ward round and if the pharmacist is not doing ward rounds? 
Comments: 
mmm (KW) 
Yes, a lot (GJ) 
I would thought that prompting a review is much more likely if you are attending a 




Which potential uses you can think of for this system? 
Can you mention anything positive and negative sides about the system? 
Comments: 
Pharmacist can benchmark their practice and see what they need to be working 
on. (..) It makes you thinking: it makes you thinking about process (LS) 
The negative is that’s quit complex (LS, KW, GJ) 
I think that could potentially lead to inter-rater problems ?you have. I know you 
guys have been working quit closely, but if you were isolated from each other 
and you came back together: would you probable be (host!)  the same way? Or 
would you think all in different ways? And what Kari thought was a review that’s 
the same as you would thought? (LS) 








Appendix 7 Free text version of care plan for patient 6-45 
 
 
CARE PLAN REVIEW WARFARIN 12.03 
 
PC- chest tightness and palpitations for last ?2 months 




Confirmed with Dr (X) letter and discharge 16/1/08, BLISTER PACK –(Community pharmacy and 
number to this) and phoned pharmacy as some changes but pack dated 21/1/08.  
Trazodone stopped due to arrhythmia last admission, fluoxetine in pack -started by GP as 
alternative.  
Warfarin - in on . Used to go in pack but was not stable so outwith pack and daughter was going 
to help with warfarin. Still outwith pack -pt now manages herself. On 1mg/2mg alt days but from 
INR written in yellow book has been unstable since discharge and some dose changes don't 




6/3 Ur 11.6, Cr 171, K 3.5, FBC ok, Trop T 0.10, INR 3.3 
 
ISSUES 
*1. Warfarin - monitor INR and try to stablise dose. Has been on 1mg od, 2mg od or 1mg/2mg alt 
since discharge but INR seems to be going up and down. ? better on 1mg most days and 2mg 
one or two days per week. (Pharm 1) 7/3 No INR yesterday - to check today, 1mg od over 
weekend (Pharm 1) 8/3 
 
*2. Renal function -weight - 58kg, est CrCl 21ml/min (ur 9.7, Cr 138 Jan ) -to cont usual meds for 
now inc furosemide and ACEI -r/v if deteriorates (Pharm 1) 7/3 
10/3 cr 157 k 4.9 - worse now 79y 58kg  est creat cl 23ml/min (Pharm 2) 10.3 
 
*3. Trop T +ve - not for further anti-coagulation, on warfarin. ? Trop T related to arrhythmia rather 
than ACS. Amiodarone was missed off so now added and for telemetry and cardiology r/v (Pharm 
1) 7/3 
 
*4. Contact community pharmacy on discharge -BLISTER PACK (Pharm 1) 7/3 
 




Appendix 8 Template version of care plan for patient 6-45 
 
 
    
 PHARMACEUTICAL CARE PLAN 
Review  
10.03  
    
 
 
[Patient identification]  
    
 
Presenting Complaints  
chest tightness and palpitations for last ?2 months 
Pharm 1
07.03  
    
 
Past Medical History 
MI, IHD, CVA, hypertension, hypothyroid,  




    
 
Relevant Drug History  
Trazodone stopped due to arrhythmia last admission, and fluoxetine 














specify if not 
oral 
Dose Frequency Sign 
 
 
Atorvastatin 20 mg Tablets 
Furosemide 40 mg Tablets 
Lisinopril 2,5 mg Tablets 
Warfarin Tablets 
GTN Spray  
Levothyroxine 100 µg Tablets 
Senna 15 mg Tablets 
Zopiclone 3,75 mg Tablets 
Fluoxetine 20 mg Tablets 
 20 mg 
40 mg 
2.5 mg 






1 x 22.00 
1 x 07.00 
1 x 07.00 
 
PRN 
1 x 07.00 
1 x 07.00 
1 x 22.00 













specify if not oral 
Dose Frequency Sign 
 
 
    [sign/ 
date]  
       












NKDA  Pharm 1
07.03]  
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 GP surgery  PODs [sign/ 
date]  
  GP letter  Nursing home   
  Discharge letter  Medical notes   
  Patient  Electronic Care Summary System  
  Patient’s family [freetext box]   
  Community pharmacy [freetext box]   
     




  Date Date Date   Date Date Date Date  
  06.03         
 Weight 58   BP      
 Height    HR      
 BMI          
 
 
Laboratory Results  
    Date Date Date Date Date Date  
 
Test Range Units 06.03 
(Exact 
time) 
     
 
 Urea 2.5-7.5 mmol/l 11.6       




3.5-5.0 mmol/l 3.5      
 
 Troponin T  µg/l 0.10       
 Free text  
 FBC   Ok       
 
INR 3.0  
(2.5-3.5) 
 3.3      
 
          




















 Action Pharm 1 
07.03 




Has been on 1mg 
od, 2mg od or 
1mg/2mg alt 
since discharge 
but INR seems to 





 [# days] 
 
  Pharm 1 
07.03 
? better on 1mg most 
days and 2mg one or 
two days per week. 
Advice on dosing 
Pharm 1
08.03 







  Pharm 1 
08.03 





 Discharge  
         
         















  Action Pharm 1 
07.03 






To cont usual 







 [# days] 
   Pharm 1 
07.03 
Monitor renal function: 
 r/v furosemide and 
ACEi if deteriorates 
Pharm 2 
10.03 
RF worse now est 
creat cl 23ml/min 
 





   Pharm 2 
10.03 
Monitor renal function: 
 r/v furosemide and 






         



















there might be 








 [# days] 
   Pharm 1 
07.03 
Contact community 








 [# days] 
   Pharm 1 
07.03 








         













  Action Pharm 1 
07.03 
? Trop T related to 









 [# days] 
   Pharm 1 
07.03 
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